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Proper GABAergic transmission through Cl-permeable GABAA receptors is fundamental for 
physiological brain development and function. Indeed, defective GABAergic signaling -due to a high 
ratio of expression of the Cl importer NKCC1 and Cl exporter KCC2- has been implicated in several 
neurodevelopmental disorders (e.g., Down syndrome, DS). Interestingly, NKCC1 inhibition by the FDA-
approved diuretic bumetanide reverts cognitive deficits in the TS65Dn mouse models of DS and core 
symptoms in a number of models of other brain disorders. However, the required chronic treatment with 
bumetanide is burdened by its diuretic side effects caused by the antagonism of the kidney Cl
-
 importer 
NKCC2, which leads to hypokalemia and jeopardizes drug compliance. Crucially, these issues would be 
solved by selective NKCC1 inhibitors, thus devoid of the diuretic effect. Starting from bumetanide’s 
structure, we applied a computational ligand-based approach to design new molecular entities that we 
tested in vitro for their capacity to selectively block NKCC1. Among the 3 newly-identified and highly 
promising NKCC1 inhibitors, one showed excellent solubility and metabolic stability in vitro. Moreover, 
analysis of WT and Ts65Dn mice systemically treated with this NKCC1 inhibitor revealed no diuretic 
effect. Finally, chronic treatment with our novel, selective NKCC1 inhibitor was able to rescue cognitive 
deficits in Ts65Dn mice in four different memory tasks, with no major signs of toxicity. Thus, our 
selective NKCC1 inhibitor devoid of the diuretic effect could represent a suitable and solid therapeutic 










1. Brain Development and the role of GABA 
Three distinct yet partially overlapping phases are involved in the establishment of neuronal circuits 
during development: an early, innate activity-independent phase, a later phase driven by spontaneous 
patterns of neuronal activity, and a final phase dependent on neuronal activity driven by sensory 
experience. During the first two phases, neuronal progenitors proliferate and differentiate, and newly born 
neurons mature morphologically and migrate to their final location in the brain, establishing a first set of 
neuronal connections (Ben-Ari, 2001; Spitzer, 2006). After the development of sensory organs, the final 
phase starts, and neuronal activity driven by sensory experience from the external environment refines the 
initial neuronal circuitry (Feller, 1999; Hadders-Algra, 2018; Leighton & Lohmann, 2016).  
GABA (γ-aminobutyric acid) is the first neurotransmitter to be functional in developing neuronal 
networks and it plays major roles in all three phases of brain development. GABA is synthesized in the 
CNS from the L-glutamic acid by the enzyme L-glutamic acid decarboxylase (GAD), which is present in 
two isoforms, GAD65 and GAD67 (Buddhala et al., 2009). GABA exerts its action by binding two 
different types of receptors: the ionotropic GABAA receptor (GABAAR) and the metabotropic GABAB 
receptor (GABABR). GABAARs are ligand-gated ion channels formed by the assembly of 5 different 
subunits. There are nineteen subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3), and they can be present in 
different combinations of five, thereby conferring GABAARs’ diverse properties with respect to ionic 
current dynamics, cellular localization, and physiological functions (Has & Chebib, 2018; Koduvayur et 
al., 2014). GABAARs are mostly permeable to chloride (Cl
-
) and they mediate slow and tonic extra-
synaptic currents or fast and phasic synaptic currents, depending on the presence of the different 
combination of the receptor subunits (Figure 1). Tonic currents are mediated by low concentrations of 
ambient GABA that escaped from the synaptic cleft and can activate subtypes of extrasynaptic GABAA 
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receptors with high affinity (Brickley et al., 1999; Cellot & Cherubini, 2013; Farrant & Nusser, 2005). 
Conversely, the phasic GABAergic inhibition occurs at the post-synaptic site of the cleft, when GABA is 
released at a high concentration from the presynaptic vesicles. During early brain development, before the 
onset of GABAergic synaptic activity, extrasynaptic tonic currents play a major role (Brickley et al., 
1999; Farrant & Nusser, 2005; Kilb et al., 2013).  
 
Figure 1Representation of the subunit composition of the GABAAR.  Different combinations of the subunits create different pool 
of synaptic and exprasynaptic receptors Modified from Jacob et al. 2008  
 
For both tonic and phasic GABAergic currents, Cl
-
 can flow through the GABAAR in both directions, 
depending on its concentration gradient across the cell membrane and the membrane resting potential of 
the neuron. In the adult CNS under physiological conditions, there is a low Cl
-
 concentration inside the 
cell. Thus, the direction of Cl
-
 flow is inward, and GABA exerts hyperpolarizing and inhibitory actions 
(Kahle et al., 2013). Conversely, during early neurodevelopment, there is a high Cl
-
 concentration inside 
the cell. Thus, opening of the GABAAR causes a Cl
-
 efflux from the cell and GABA depolarizes the 
membrane (Kahle et al., 2013). This depolarization leads to activation of voltage-gated calcium channels 
and removal of the Mg
2+
 block from NMDA receptors, causing further membrane depolarization and 
calcium influx into the cell. This is vital for the activation of second messengers that participate in 
neuronal migration, differentiation and synaptogenesis (Ben-Ari, 2002, 2014; Cellot & Cherubini, 2013; 
Leinekugel et al., 1997; Takayama & Inoue, 2010).  
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Later in development, when the first coarse connectivity among developing neurons is built, depolarizing 
GABA also controls spontaneous neuronal activity in the form of network action potential bursts of 
different shapes across brain areas and species. Interestingly, these bursts of spontaneous neuronal 
activity during development have been described in the rodent, chick, turtle, ferret and rabbit (Aguado et 
al., 2003; Ben-Ari, 2001; Wong, 1999). Moreover, evidence exists that in primate fetuses there is a 
complex hippocampal network capable of generating spontaneous and paroxysmal synchronized activities 
in utero (Khazipov et al., 2001). Interestingly, early patterns of neuronal synchronized activity have also 
been described in humans (preterm babies) by EEG and fMRI studies (Arichi et al., 2017; Khazipov & 
Luhmann, 2006; Tolonen et al., 2007). Nevertheless, the contribution of depolarizing GABA during these 
early patterns of neuronal activity in humans has not been investigated yet.  
Notably, when GABA switches its action from depolarizing and mostly excitatory to hyperpolarizing and 
inhibitory later in life, the neuronal network activity oscillations disappear ((Leitch et al., 2005), but see 
(Makinen et al., 2018)) for in vitro evidence in human pluripotent stem cell-derived neural culture). 
Interestingly, for at least some brain structures, this phenomenon coincides with the development of 
complex behavior related to that specific brain structure. For example, the striatum completes its 
immature activity patterns precisely when pups begin coordinated locomotor behavior (Dehorter, Vinay, 
et al., 2012).  
Finally, proper GABAergic transmission is fundamental during critical periods of enhanced neuronal 
connectivity and plasticity driven by sensory system experiences deriving from individuals’  own life 
experiences (M. R. Begum & Sng, 2017; Berardi et al., 2000; Hensch, 2004; Hensch & Fagiolini, 2005; 
Hensch & Quinlan, 2018; Sommeijer et al., 2017; Takesian & Hensch, 2013; H. Zhang et al., 2018).  
2. Chloride transporters in physiological brain development 
The understanding of the mechanisms regulating intracellular Cl
-
 concentration during development has 
gained a lot of attention in recent years because of the fundamental role of Cl
-
 in modulating GABAergic 
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transmission and its consequent implication in neurodevelopmental processes. In neurons, the main 
regulators of Cl
-
 homeostasis are the cation-chloride co-transporters (CCCs) (Blaesse et al., 2009; H. Li et 
al., 2002), especially the sodium-potassium-chloride cotransporter isoform 1 (NKCC1) and the 
potassium-chloride symporter isoform 2 (KCC2). NKCC1 is highly expressed in immature neurons 
during development, as it transports Cl
-
 inside the cells, leading to a high intracellular Cl
-
 concentration 
( ̴30 mM), and depolarizing and mostly excitatory GABA actions (Achilles et al., 2007; Dzhala et al., 
2005) (Figure 2, left). On the other hand, KCC2 is highly expressed in mature neurons, where it keeps the 
intracellular Cl
-
 level at low values (4-6 mM; (Delpire & Kahle, 2017), thereby determining the 
hyperpolarizing and inhibitory GABA action (Ben-Ari, 2002, 2014; Rivera et al., 1999; Stein et al., 2004) 
(Figure 2, right). 
 
Figure 2. Representation of the different CCCs expression in embryonic (left) and adult (right) neurons. Left: The high NKCC1 
expression during early development leads to a high Cl- concentration inside the cells, thus determining a Cl- efflux when 
GABAAR opens and the cell depolarization. Right: In the adulthood the high KCC2 expression determine a low Cl
- concentration 
inside the cell. When GABAAR opens, the Cl
- influx in the cell determine the neuron hyperpolarization.       
 
Interestingly, this pattern of expression for NKCC1 and KCC2 develops earlier in the evolutionary older 
structures (e.g., spinal cord, brainstem, hypothalamus; (Watanabe & Fukuda, 2015) (Figure 3). Indeed, 
NKCC1 and KCC2 are highly expressed in the mouse spinal cord from E11.5-E13.5 (Delpy et al., 2008) 
and starting from E15.5, NKCC1 decreases its expression, while KCC2 remains highly expressed. This 
difference generates the depolarizing to hyperpolarizing GABA switch in motor neurons around E17.5 
(Branchereau et al., 2002). Notably, recordings at E18.5 in mice showed that motorneurons exhibited 
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GABA and glycine (that also binds to Cl
-
-permeable ionic receptors) excitation in the absence of KCC2, 
thus highlighting its importance in inhibitory activity (Hubner et al., 2001).  
In the hypothalamus, the presence of NKCC1 mRNA expression was not clear in rodent embryos, and its 
expression was weak postnatally. Conversely, at E14.5, KCC2 mRNA is strongly present and maintains 
its expression into adulthood in rodents (H. Li et al., 2002; C. Wang et al., 2002). 
In the thalamus, NKCC1 mRNA is not present during the embryonic stages in rats (C. Wang et al., 2002). 
Conversely, KCC2 mRNA is already found at E12 in rodents, when the region begins forming, with the 
exception of the dorsomedial part, which expresses KCC2 later at E18 (H. Li et al., 2002; C. Wang et al., 
2002; Watanabe & Fukuda, 2015). Notably, NKCC1 mRNA is stably expressed postnatally in rats (from 
soon after birth into adult life), suggesting a possible low hyperpolarizing or even depolarizing action of 
GABA in the adult thalamus (C. Wang et al., 2002; Watanabe & Fukuda, 2015). 
In the rat cerebellum, NKCC1 mRNA was not detected in early developing Purkinje cells at any postnatal 
age. Conversely, KCC2 mRNA was found at E15.5 in mouse Purkinje cells and at P1 in rat Purkinje cells 
when the cells begin differentiation (Mikawa et al., 2002). Interestingly, NKCC1 mRNA was observed in 
rats in the external granule layer, where the immature granule cells (later developing in comparison to 
Purkinje cells) are located at P7 and P14, and in the internal granular layer in post-migratory granule cells 
after P7 (Mikawa et al., 2002). Moreover, KCC2 transcripts were detectable already at P3 in mouse and at 
P7 in rat granule cells (Mikawa et al., 2002; Stein et al., 2004). 
In the rat hippocampus, NKCC1 mRNA is strongly present in the neuroepithelium at E18 (Watanabe & 
Fukuda, 2015), peaking in the first postnatal week and then decreasing by P14-P15 (Pfeffer et al., 2009; 
Plotkin et al., 1997; C. Wang et al., 2002). Instead, KCC2 mRNA signals can be detected first in the CA3 
region at E15.5 and in the CA1 region at E18.5 in mice; it then reaches adult levels at P15 (Stein et al., 
2004). In the same study, western blot analysis showed a time course of KCC2 protein expression closely 
parallel to the detection of the KCC2 transcript described above (Stein et al., 2004).  
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In the neocortex, NKCC1 transcripts have been detected as early as E12.5 in scattered cells of the mouse 
neuroepithelium and in the ventricular zone (VZ) of the ganglionic eminences (H. Li et al., 2002; 
Watanabe & Fukuda, 2015) where the neuronal progenitors are located. By E14.5, NKCC1 mRNA is 
upregulated in the proliferative zones of the lateral and medial ganglionic eminence in mice (Watanabe & 
Fukuda, 2015). Then, NKCC1 expression in the VZ decreases in late mouse embryonic development 
(E17-P0; (Caviness et al., 1995)). In the differentiated cells of the cortical plate both mRNA and protein 
of NKCC1 are strongly present in rats (Li et al., 2002; (Watanabe & Fukuda, 2015)). Interestingly, KCC2 
mRNA signals are not detected in the mouse neocortex until P0 (H. Li et al., 2002; C. Wang et al., 2002). 
Although most of the work on the presence or absence of the CCCs is based on mRNA evidence, some 
data on the protein expression are available for the rat neocortex. In particular, NKCC1 is highly 
expressed postnatally between P3-P14, whereas KCC2 is expressed at low levels during the first two 
weeks after birth and is upregulated by P21 (Dzhala et al., 2005).  
Finally, NKCC1 is highly expressed both in the developing and adult choroid plexus in mice and rats 
(Kanaka et al., 2001; H. Li et al., 2002). There, NKCC1 is located on the apical membrane of epithelial 
cells and it plays a key role in the formation of the cerebrospinal fluid (CSF). Conversely, KCC2 is not 




Figure 3. Representation of the different expression profiles of NKCC1 (left) and KCC2 (right) in the CNS. DLG: dorsal lateral 
geniculate nucleus; HP: hippocampus; VLP: ventral posterior thalamic nucleus. From Watanabe and Fukuda 2015.  
 
The developmental expression profiles of NKCC1 and KCC2 have also been investigated in humans. At 
the mRNA level, both NKCC1 and KCC2 increased with gestational age across the second trimester and 
after birth in the prefrontal cortex, while only KCC2 increased in the hippocampus across the second 
trimester, but both NKCC1 and KCC2 increased after birth (Hyde et al., 2011). A more recent study 
instead found lower levels of NKCC1 mRNA during the prenatal period (10 post conception week 
(PCW)-birth) with an increase in the postnatal age (birth-90 years) in the 16 brain areas analyzed 
(Sedmak et al., 2016). At the protein level, the expression of NKCC1 in the time window between PCW 
31-41 was high with a peak at PCW 35 and decreased from the first year of life (PCW 54-92) to 
adulthood in the parietal cortex. KCC2 expression was low during the entire fetal and neonatal period 
(PCW 20-41) and increased over the first year of life (Dzhala et al., 2005). Nevertheless, other studies 
found a robust presence of both KCC2 mRNA and protein during the second half of gestation in the 
neocortex, indicating that high KCC2 expression starts prenatally (Kaila et al., 2014). Notably, expression 
of KCC2 was observed as early as PCW16 in a subset of subplate neurons (Bayatti et al., 2008). 
Moreover, KCC2-immunoreactive neurons were described in the hippocampus and entorhinal cortex as 
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early as PCW 25 (which was the earliest age tested), and these neurons reach adult levels during the first 
six postnatal months (Dzhala et al., 2005; Sedmak et al., 2016). Interestingly, the overall ratio of NKCC1 
to KCC2 is very high in pediatric human brains, and it decreases until approximately 2 years of life and 
then it remains at the adult levels (Jansen et al., 2010). 
2.1. The role of NKCC1 and KCC2 in neuronal proliferation, migration and network 
integration.  
The important roles of NKCC1 and KCC2 in driving and regulating fundamental processes of proper 
brain development has been widely demonstrated in rodents by diverse experimental approaches ranging 
from knock out (KO) animals to modulating the expression and/or the activity of the two CCCs by 
pharmacological inhibition (e.g., with the widely used FDA-approved drugs bumetanide and furosemide), 
RNA interference, overexpression  (Schulte et al., 2018).  
2.1.1 NKCC1 plays a key role in cell proliferation and apoptosis 
The role of NKCC1 in brain cell proliferation has been demonstrated by a number of studies. In 
particular, ex vivo investigations have shown that NKCC1 is expressed in radial glial cells in rats 
(progenitors of excitatory cortical neurons; (H. Li et al., 2002; Noctor et al., 2001) in the cortex, although 
it is not in βIII-tubulin- (a marker of post-mitotic neurons) positive regions (H. Li et al., 2002). 
Interestingly, NKCC1 is highly expressed also in the ganglionic eminence, the brain region that gives 
birth to GABAergic interneurons (H. Li et al., 2002). In agreement with the abovementioned studies, 
NKCC1 knockdown mice have defects in the proliferation of neural precursor cells of the SVZ (Young et 
al., 2012) (Figure 4) and in the proliferation of the neural progenitors of the lateral ganglionic eminences 
(Magalhaes & Rivera, 2016). Moreover, pharmacological blocking of NKCC1 with bumetanide inhibits 
cell proliferation in neuronal precursors of the subventricular zone in mice (Sun et al., 2012). The role of 
NKCC1 in brain cell proliferation has been demonstrated also in vitro in mouse oligodendrocyte 





Figure 4. NKCC1 KO in NPCs of the olfactory bulb results in a reduction of neuron production. RFP indicate the electroporated 
neurons with respectively shRNA control (shControl) or the shRNA against NKCC1 (shNKCC1). RMS: rostral migratory 
stream; GCL: granule cell layer. Scale bar: 100µm. Adapted from Young et al. 2012.  
 
Another fundamental stage where NKCC1 plays a role is programmed cell death during development. In 
particular, NKCC1 is implicated in the activity-regulated cell death in Cajal-Retzius neurons, a population 
that mostly disappears by apoptosis early in life in the mouse developing cortex (Blanquie et al., 2017). 
Pharmacological inhibition of NKCC1 by bumetanide in vitro or genetic deletion of the cotransporter in 
vivo (NKCC1−/− mice) rescued the population of Cajal-Retzius neurons from apoptosis (Blanquie et al., 
2017). 
2.1.2 NKCC1 and KCC2 regulate neuronal migration 
The depolarizing GABA transmission by high expression of NKCC1 in the ventricular zone and cortical 
plate (Shimizu-Okabe et al., 2002) plays a role in the migration of newly generated rat cortical neurons 
(Behar et al., 1996; Behar et al., 1998; Heck et al., 2007). In particular, both knocking down of NKCC1 
(shRNA) and pharmacological manipulations of NKCC1 by bumetanide in neuroblasts in mice from the 
rostral migratory stream in organotypic slice cultures reduced migratory speed without affecting the 
direction of the migration (Mejia-Gervacio et al., 2011). Although this piece of evidence points to a 
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possible role for NKCC1 in physiological interneuron migration, a direct demonstration of the 
involvement of NKCC1 in cortical excitatory-neuron migration is still missing. Indeed, the knockdown of 
NKCC1 in vivo in mice during neurodevelopment through in utero electroporation resulted in a disruption 
of cortical neuron morphology, but unfortunately, neuronal migration was not evaluated in that same 
study (D. D. Wang & Kriegstein, 2008). Nevertheless, several lines of evidence suggest that altered 
expression of NKCC1 underlies cortical malformations and neuronal ectopy in pathological conditions 
(Fukuda & Wang, 2013; Koyama et al., 2012; Shimizu-Okabe et al., 2007). In particular, high expression 
of NKCC1 and low expression of KCC2 were found in cortical plate neurons involved in micro-gyral 
cortical malformations in rodents in vivo (Fukuda & Wang, 2013; Shimizu-Okabe et al., 2007). Moreover, 
either knockdown of NKCC1 by RNA interference or its pharmacological inhibition by bumetanide both 
rescued the migration deficits of granule cells in the dentate gyrus in a rat model of febrile seizures in vivo 
(Koyama et al., 2012). Furthermore, some evidence indicates a role for NKCC1 in the migration of 
glioma cells both in vitro and in vivo in mice (Haas & Sontheimer, 2010). While these in vivo studies 
suggest that high NKCC1 expression could affect neural migration and pathological conditions, it is not 
clear whether physiological levels of NKCC1 regulate migration in vivo in non-pathological conditions.  
 
Similar to the case of NKCC1, some evidence exists that KCC2 also mediates migration of interneurons, 
where its upregulation works as a stop signal both in vitro and in vivo in mice (Figure 5) and in 
organotipic cultures from a ferret model of cortical dysplasia (Abbah & Juliano, 2014; Bortone & 
Polleux, 2009; Inamura et al., 2012; Miyoshi & Fishell, 2011). On the other hand, KCC2 expression in 
excitatory neurons increases only after they have completed their migration across different cortical layers 
and other brain areas in rats (Cancedda et al., 2007). In agreement with these data, overexpression of 
KCC2 in newly born excitatory cortical neurons did not affect their migration in rats (Cancedda et al., 
2007). Nevertheless, this may possibly be because high levels of taurine inhibit KCC2 function at 
embryonic stages, thus preserving the depolarizing GABA signaling (Inoue et al., 2012). Interestingly, a 
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structural role for KCC2 in neural crest cell migration and early radial glia migration in mice (at E9.5) 
was reported to occur through the interaction with the cytoskeleton-associated protein 4.1N and 
independently of the ion-transport action (Horn et al., 2010).  
 
Figure 5. Precocious KCC2 expression reduced migration of interneuron. B: Interneurons electroporated with EGFP (control) 
showed a robust migration from medial ganglionic eminence (MGE) to the cortex. C: Interneurons expressing precocious KCC2 
showed a marked reduced migration to the cortex. Adapted from Bortone and Polleux 2009. 
 
2.1.3 NKCC1 and KCC2 regulate neuronal morphological maturation  
Both NKCC1 and KCC2 play fundamental roles in neuronal branching and in the establishment, 
maintenance and plasticity of synapses (Kaila et al., 2014; Khalilov et al., 2011; Sedmak et al., 2016). In 
particular, a high Cl
-
 concentration maintained by the high expression of NKCC1 and the low expression 
of KCC2, is fundamental for neuronal morphological maturation. 
For example, NKCC1 was observed in the tip of growing neurites (K. Nakajima et al., 2007), and both its 
knockdown by RNA interference (K. Nakajima et al., 2007; K. Nakajima et al., 2011a, 2011b) or its 
pharmacological inhibition by treatment with bumetanide (K. I. Nakajima & Marunaka, 2016) abolished 
neurite outgrowth in vitro in PC12 cells. Accordingly, knockdown of NKCC1 in vivo disrupted the 
dendritic maturation of mouse cortical neurons (D. D. Wang & Kriegstein, 2008; Young et al., 2012) 
(Figure 6A). Moreover, NKCC1 activation is also required for neurite growth in injured rodent adult 
neurons in vivo (Modol et al., 2015; Pieraut et al., 2007; Pieraut et al., 2011). Furthermore, NKCC1 has 
been involved in the maturation of both rodent excitatory and inhibitory synapses (Nakanishi et al., 2007; 
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Pfeffer et al., 2009; D. D. Wang & Kriegstein, 2008). Although NKCC1 -/- mice do not exhibit 
morphological alteration of hippocampal dendritic arborization, they presented delayed maturation of 
GABAergic and glutamatergic synapses (Pfeffer et al., 2009). Accordingly, in utero NKCC1 knockdown 
in mouse excitatory cortical neurons affected the physiological development of excitatory and inhibitory 
synapses (D. D. Wang & Kriegstein, 2008). Moreover, pharmacological NKCC1 inhibition by 
bumetanide during mouse cortical development disrupted AMPA synapse maturation, although it did not 
affect NMDA receptor signaling (D. D. Wang & Kriegstein, 2011).  
In line with studies on NKCC1 downregulation/inhibition, premature expression of KCC2 by in utero 
electroporation in a subpopulation of rat cortical neuron progenitors severely impacted morphological 
maturation, with fewer and shorter neurites ((Cancedda et al., 2007) (Figure 6B); but see (Fiumelli et al., 
2013)) together with an altered number of dendritic spines (Fiumelli et al., 2013). Moreover, 
overexpression of KCC2 in utero also increased the number of dendritic spines (Fiumelli et al., 2013). 
Interestingly, KCC2 is highly expressed in the head of rodent dendritic spines, where AMPA and NMDA 
receptors are located; there, it also plays a role in the maintenance of glutamatergic synapses (Blaesse & 
Schmidt, 2015; Chamma et al., 2012). Notably, KCC2 exerts this role independently of its Cl
-
 transporter 
activity and via interaction with the submembrane actin cytoskeleton by binding to 4.1 N protein in mice 
(H. Li et al., 2007). Further studies showed that KCC2 constrains lateral diffusion of AMPA receptors 
and regulates their content at the spine again through the regulation of actin dynamics (Chevy et al., 2015; 
Gauvain et al., 2011; Llano et al., 2015). In agreement with previous studies, KCC2 knockout mice 
exhibit large alterations in synaptic and neuronal network activity in the CA3 region of the hippocampus 




Figure 6: Both NKCC1 downregulation (A) and KCC2 premature upregulation (B) caused impaired dendrite branching. A: 
Representative reconstruction of neurons electroporated with shRNA control (shControl; left) and shRNA against NKCC1 
(shNKCC1; right). Adapted from Young et al 2012. B: Representative reconstruction of neurons electroporated with EGFP (left) 
or KCC2-EGFP (right). Scale bar: 100µm. Modified from Cancedda et al. 2007. 
 
Finally, premature KCC2 overexpression found in a rat model of atypical febrile seizures and in a variant 
of KCC2 found in an Australian family with febrile seizures cause a reduction in dendritic spine number 
(Awad et al., 2016; Puskarjov, Seja, et al., 2014) Interestingly, the reduction of the premature KCC2 
expression rescued the alterations in spine density and morphology and the seizure susceptibility in the 
same rat model of febrile seizures (Awad et al., 2016).  
2.2. The role of NKCC1 and KCC2 in the critical period of brain plasticity 
The critical period for sensory system plasticity has been widely investigated in the visual system, starting 
from the pioneering studies of Hubel and Wiesel in the middle part of the 20
th
 century [or, late 1950’s]. 
Interestingly, proper development of GABAergic transmission is crucial for both the opening and the 
closure of the critical period plasticity in the visual cortex. Indeed, manipulation of inhibition, by 
prematurely enhancing or reducing GABAergic signaling during development interferes with the onset of 
the rodent critical period plasticity (Fagiolini et al., 2004; Fagiolini & Hensch, 2000; Huang et al., 1999; 
Iwai et al., 2003). Notably, reducing GABAergic activity in adult animals reopens the critical period in 
the visual cortex (Harauzov et al., 2010). More recently, Deidda and colleagues demonstrated that 
depolarizing GABA during early postnatal development plays a pivotal role in the critical period for 
visual cortical plasticity later in life. In particular, they observed that pharmacological inhibition of 
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NKCC1 with bumetanide from P3 to P8 in rats extended the duration of the critical period into adulthood, 
with a mechanism dependent on the neurotrophin BDNF (Deidda, Allegra, et al., 2015). 
2.3. Expression and role of other NKCCs and KCCs in the developing brain. 
In addition to NKCC1, the NKCC family also contains NKCC2. NKCC2 is highly expressed in the apical 
membrane of the epithelial cells of the thick ascending limb in the kidney and the macula densa cells 
(specialized sensor cells detecting changes in the fluid composition of the distal tubule), where it 
facilitates the reabsorption of sodium and Cl
-
 ions into the blood (Delpire & Gagnon, 2018; A. Edwards et 
al., 2014). Moreover, NKCC2 is strongly expressed in the epithelial layer of the endolymphatic sac in 
humans, a part of the vestibular system (Kakigi et al., 2009). Notably, NKCC2 immunoreactivity is also 
present in vasopressinergic and oxytocinergic neurons in the hypothalamo-neurohypophyseal system in 
the rat brain (Konopacka et al., 2015). Blockade of NKCC2 leads to pronounced natriuresis, kaliuresis 
and diuresis (Becker et al., 2003; Castrop & Schiessl, 2014; Gamba & Friedman, 2009; Hannemann et al., 
2009; Schiessl & Castrop, 2015). Loss of function mutations of the gene coding for NKCC2 result in 
Bartter's syndrome, which is characterized by hypokalemic alkalosis, hyponatremia and hypotension 
(Simon et al., 1996).  
The less studied members of the KCC family (KCC1, KCC3 and KCC4) are also expressed in the 
developing brain. KCC1 mRNA was exclusively detected in the choroid plexus during mouse brain 
development (H. Li et al., 2002), but mRNA levels have been found in neuronal and glial cells in diverse 
regions (olfactory bulb, hippocampus, choroid plexus, posterior hypothalamic nucleus) of the adult rat 
CNS in vivo (Kanaka et al., 2001). Interestingly, KCC1 negatively regulates NGF-induced neurite 
outgrowth in vitro in PC12 cells (Nagao et al., 2012). KCC3 mRNA is weakly represented in the 
embryonic rodent brain (H. Li et al., 2002), but both the mRNA and the protein are widely present in 
adult cortical, hippocampal, brainstem and cerebellar Purkinje neurons (Pearson et al., 2001; Shekarabi et 
al., 2011). Moreover, KCC3 protein is expressed in white matter-rich structures in the rodent brain, spinal 
cord and peripheral nerves, indicating a role of KCC3 in myelination (Pearson et al., 2001). Furthermore, 
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KCC3 regulates the cell volume in mouse peripheral nerve fibers (Flores et al., 2018). In agreement with 
the previous findings, KCC3 −/− mice exhibited axonal swelling, hypomyelination and demyelination in 
sciatic nerves (Byun & Delpire, 2007; Howard et al., 2002). Interestingly, these mice recapitulate most of 
the symptoms of human peripheral neuropathy associated with agenesis of the corpus callosum (ACCPN, 
also known as Andermann syndrome). This severe sensorimotor neuropathy is characterized by 
locomotor abnormalities and areflexia and has been associated with loss-of-function mutations in KCC3 
gene (Bowerman et al., 2017; Howard et al., 2002; Uyanik et al., 2006).  
KCC4 is highly expressed in the embryonic mouse brain, including choroid plexus, peripheral ganglia, 
ventricular zones and the nucleus of the trigeminal nerve (H. Li et al., 2002). Along with NKCC1, KCC4 
plays a role in cochlear development, as KCC4 KO mice exhibit deafness. KCC4 loss possibly exerts that 
effect by causing the death of hair cells by osmotic perturbation or membrane depolarization (Boettger et 
al., 2002).  
Spatiotemporal expression of the KCC transporters has been studied also in humans. In particular, KCC1 
mRNA was first observed in the cortex of the cerebellum at embryonal stages (between PCW 10-13) and 
also found in other brain regions (hippocampus, striatum and thalamus between PCW 21 and birth; 
(Sedmak et al., 2016). KCC3 mRNA was described in the cortex, cerebellum, hippocampus, amygdala, 
striatum and thalamus in all the stages of development and adulthood (age range: 5 PCW–82 years; 
(Sedmak et al., 2016). KCC4 mRNA was detected at low levels in the cortex both at prenatal and 
postnatal ages (Kaila et al., 2014), but not detected in a subsequent study in any brain region (Sedmak et 







3. Chloride transporters in neurodevelopmental disorders 
Neurodevelopmental disorders (NDs) are chronic psychiatric/neurological conditions that affect 4-5% of 
the population (Mitchell, 2011). In general, NDs result from an altered timing and asynchrony of 
developmental processes induced by both genetic and environmental factors, which cause defective 
growth of the central nervous system. Although they display very different etiologies, most of the NDs 
share a number of features (e.g., impairments in learning, memory, emotional regulation, sociality, and 
self-control) and some comorbidity (e.g., increased seizure susceptibility and sleep disorders). 
Interestingly, many of these common features have been associated with common alterations in 
GABAergic transmission. In particular, several studies demonstrated a high intracellular Cl
-
 concentration 
and a depolarizing GABA action attributable to an altered NKCC1/KCC2 ratio in a wide range of NDs 
(Figure 7), including epilepsy, autism spectrum disorders, Asperger syndrome, Rett syndrome, Fragile X 
syndrome, schizophrenia, tuberous sclerosis complex, traumatic brain injury, glioma and Down syndrome 
(Ben-Ari, 2017; Jaggi et al., 2015; Medina et al., 2014; Schulte et al., 2018; Wu, Che, et al., 2016). 
 
Figure 7: Representative cartoon of the NKCC1/KCC2 ratio expression in physiological and pathological development. High 
expression ratio of NKCC/KCC2 leads to a shift in the GABA polarity trough more depolarized values determining less 
inhibitory and depolarizing GABA action, implicated in several neurological disorder. Adapted from Jaggi et al. 2015. 
  
Interestingly, restoration of physiological Cl
-
 concentration by pharmacological intervention aimed at 
inhibiting NKCC1 or enhancing KCC2 activity has led to positive outcomes in rodent models and patients 
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with these conditions (Ben-Ari, 2017; Jaggi et al., 2015; Medina et al., 2014; Schulte et al., 2018). 
Currently, the most used approach to restore intracellular Cl
-
 concentration in mouse models of brain 
pathologies as well as in clinical studies in patients has been the inhibition of NKCC1 with bumetanide. 
Another recently investigated option to restore intracellular Cl
-
 concentration has been the enhancement 
of KCC2 activity by the compound CLP257. This has been explored in cultured cell lines and in spinal 
cord slices obtained from rats with peripheral nerve injury, a condition characterized by KCC2 
hypofunction (Gagnon et al., 2013). Interestingly, CLP257, by modulating KCC2 activity, was also able 
to exert an antinociceptive action in rats with peripheral nerve injury (Gagnon et al., 2013). Nevertheless, 
a recent study showed that CLP257 was not able to modulate KCC2 activity in vitro in the same cultured 
cell line used previously, opening the possibility that the behavioral effects of CLP257 observed by 
Gagnon and colleagues may be independent of KCC2 modulation (Cardarelli et al., 2017). Again, this 
study was challenged by Gagnon and colleagues, who replied to the Cardarelli and co-workers objection 
confirming their previous findings (Gagnon et al., 2017), thus indicating the need for further 
investigation.  
Finally, recent studies evaluated other components involved in NKCC1 and KCC2 regulation that could 
be considered in the future as possible therapeutic targets. For example, the insulin-like growth factor-1 
was able to decrease the NKCC1/KCC2 ratio in developing rat neurons in vivo, promoting the GABA 
switch from depolarizing to hyperpolarizing (Baroncelli et al., 2017). Moreover, the kinase WNK-SPAK, 
which can activate NKCC1 and deactivate KCC2 through its phosphorylation state (Kahle et al., 2010), 
could also be an interesting target to modulate the NKCC1/KCC2 ratio (de Los Heros et al., 2014; Kahle 
et al., 2015).  
Here, we give a brief description of the involvement of altered NKCC1 and KCC2 expression/function in 
the pathogenesis of some neurodevelopmental disorders, considering some examples of therapeutic 
approaches. We describe more in detail the case of  Down syndrome at the end of this section.  
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3.1. Epilepsy  
Epilepsy is a neurological disorder characterized by epileptic seizures. These are caused by altered, 
excessive or hypersynchronous neuronal activity in the brain (Chang & Lowenstein, 2003). Several pieces 
of evidence suggest that neuronal hyperexcitability and hypersynchronization is the result of an alteration 
of the delicate balance between excitatory and inhibitory synaptic activity. Interestingly, an imbalance in 
NKCC1 and KCC2 activity together with depolarizing GABAergic action have been observed in several 
animal models of epilepsy (Ben-Ari, 2017; Di Cristo et al., 2018). The first lines of evidence about the 
involvement of CCCs in epileptogenic activity came from the late 90s, when four independent studies 
found that the antagonism of NKCC1 with furosemide or bumetanide caused a block of epileptic activity 
both in vitro and in vivo in rats (Hochman et al., 1995; Hochman et al., 1999; Hochman & Schwartzkroin, 
2000; Schwartzkroin et al., 1998). In 2002, four other works demonstrated the direct relationship between 
NKCC1, KCC2 and epileptic pathogenesis. In particular, high NKCC1 expression was indicated as a 
factor influencing the increased susceptibility to seizures in the developing brain. In this study, 
bumetanide administration was able to rescue epileptiform activity both in vitro and in vivo during 
development in rodents (Dzhala et al., 2005). Moreover, increased expression of NKCC1 was found in 
the amygdala-kindling model of seizures in rats (Okabe et al., 2002). Furthermore, a decrease in KCC2 
expression was found in the mouse hippocampus after kindling-induced seizures (Rivera et al., 2002). 
Finally, mice deficient in KCC2 showed frequent seizures (Woo et al., 2002). This may be possibly due to 
a shift in the reversal potential for GABAAR-driven Cl
-
 currents (ECl), which leads to smaller GABAAR 
hyperpolarization and/or to less reuptake of potassium and chloride during high-frequency spikes (Woo et 
al., 2002). Stemming from these first works, several other studies in rodent models confirmed the 
involvement of an altered NKCC1/KCC2 ratio in the pathogenesis of epilepsy. A number of these 
studies also confirmed positive outcomes upon bumetanide treatment (Almeida et al., 2011; Amadeo 
et al., 2018; Baek et al., 2016; Cleary et al., 2013; Dzhala et al., 2008; Dzhala et al., 2010; D. A. 
Edwards et al., 2010; Eftekhari, Mehrabi, et al., 2014; Hu et al., 2017; Kelley et al., 2018; Koyama et 
al., 2012; X. Li et al., 2008; Loscher et al., 2013; MacKenzie & Maguire, 2015; MacKenzie et al., 
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2016; Marguet et al., 2015; Mazarati et al., 2009; Nardou et al., 2009; Reid et al., 2013; Robel et al., 
2015; Santos et al., 2017; Sivakumaran & Maguire, 2016; Tao et al., 2016; Tollner, Brandt, Erker, et 
al., 2015; F. Wang et al., 2017; J. Zhang et al., 2016). 
Interestingly, an imbalance in the NKCC1/KCC2 ratio is also present in human patients. First, 
upregulation of NKCC1 and/or downregulation of KCC2 was found in the hippocampal subiculum and 
hippocampi obtained from patients affected by temporal lobe epilepsy (Huberfeld et al., 2015; Huberfeld 
et al., 2007; Munoz et al., 2007; Palma et al., 2006; Sen et al., 2007).  Then, other studies found altered 
expression of NKCC1 and/or KCC2 in the cortical malformation of patients affected by medically 
intractable epilepsy (Aronica et al., 2007; Sen et al., 2007; Shimizu-Okabe et al., 2011) in hypothalamic 
hamartoma, a rare epileptogenic lesion associated with gelastic seizures (D. Y. Kim et al., 2008), in 
cortical samples from epileptic children (Jansen et al., 2010), and in peritumoral tissues with high seizure 
susceptibility (Conti et al., 2011; Pallud et al., 2014). Notably, an increased expression of NKCC1 and a 
decreased expression of KCC2 were observed also in brain samples obtained from patient affected by 
Dravet syndrome, an infantile encephalopathy characterized by severe epilepsy and cognitive impairment 
(Ruffolo et al., 2018). Interestingly, bumetanide treatment ameliorated seizure frequency in temporal lobe 
epilepsy (Eftekhari, Mehrabi, et al., 2014). Moreover, bumetanide was able to reduce seizure duration and 
frequency in a child affected by intractable multifocal seizures (Kahle, Barnett, et al., 2009). 
Nevertheless, the NEMO trial, assessing the efficacy and safety of the use of bumetanide for the treatment 
of acute neonatal encephalopathy seizures (Pressler et al., 2015), was recently interrupted due to poor 
bumetanide antiepileptic action and ototoxicity (Ben-Ari et al., 2016). Moreover, the involvement of 
KCC2 in the pathogenesis of epilepsy has been recently questioned based on conflicting results showing 
increased KCC2 expression in epileptic brain tissue from both human (Jansen et al., 2010; Karlocai et al., 
2016) and rodent models (Awad et al., 2016; Galanopoulou, 2008; Khirug et al., 2010). Nevertheless, the 
conflicting results showed both decreased and increased KCC2 expression in epilepsy; this discrepancy 
could depend on brain region, stage of disease, gender, or the influence of seizures themselves (Di Cristo 
25 
 
et al., 2018). Thus, although the involvement of alterations of NKCC1 and KCC2 expression/activation in 
epilepsy is clearly demonstrated, deeper studies to better investigate their delicate modulation and assess 
the possibility of targeting them with pharmacological approaches are still required.  
3.2. Autism Spectrum Disorders  
Autism spectrum disorders (ASD) are a group of syndromes characterized by different etiologies, but 
common core symptoms (e.g., repetitive behaviors, deficits in social interaction and language impairment; 
(Pizzarelli & Cherubini, 2011), suggesting that possibly there are common mechanisms underlying ASD 
pathology. Moreover, ASD can be comorbid with other neurodevelopmental syndromes such as epilepsy 
(M. L. Lewis et al., 2018), Rett syndrome (Percy, 2011), Fragile X syndrome (Kaufmann et al., 2017), or 
Down syndrome (J. Moss et al., 2013). Several pieces of evidence, both from rodent models and humans, 
indicate that commonly altered GABAergic transmission could underlie ASD pathology (Cellot & 
Cherubini, 2014). In particular, the pioneering observation of a paradoxical effect upon the administration 
of GABAA-signaling-enhancing benzodiazepine diazepam in autistic children (e.g., anxiety and 
aggression (Marrosu et al., 1987), suggested the possibility of depolarizing GABA action in ASD. This 
idea prompted researchers to test whether the inhibition of NKCC1 by bumetanide could be a valid 
therapeutic strategy in five autistic children (Lemonnier & Ben-Ari, 2010). The amelioration of some 
behavioral aspect related to ASD upon bumetanide treatment opened the way for a larger clinical trial 
designed for 54 autistic patients (Lemonnier et al., 2012) and consequently a phase II clinical study 
(Lemonnier et al., 2017). These studies confirmed that bumetanide is able to ameliorate the core 
symptoms of ASD. Moreover, bumetanide resulted efficient in the treatment of a young girl with 
Asperger syndrome, a neurodevelopmental disorder belonging to ASD (Grandgeorge et al., 2014). In 
parallel to the clinical studies, KCC2 expression was altered in the VPA rat model of ASD. Interestingly, 
bumetanide administration in VPA-treated pregnant rats resulted in the rescue of core behaviors related to 
ASD in their offspring (Eftekhari, Shahrokhi, et al., 2014; Tyzio et al., 2014). Nevertheless, the lack of 
studies addressing bumetanide treatment at developmental stages that can be compared to those of 
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patients in clinical trials and the paucity of mouse models of autism tested among the many that exist, 
highlights the need for further investigation.  
3.3. Rett Syndrome  
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the X-linked Methyl-
CpG-binding protein (MECP2) gene. Mecp2 is a regulator of the transcription of a number of genes by 
promoter methylation. Individuals affected by RTT grow normally until the age of 6-18 months but then 
develop various symptoms (e.g., cognitive impairment, seizures, altered motor function and stereotypic 
behaviors; (Ehinger et al., 2018). As for autism, several pieces of evidence indicate a possible alteration in 
the GABAergic signaling in RTT rodent models and humans (Cellot & Cherubini, 2014). The first 
evidence regarding alterations in the NKCC1/KCC2 balance came from a study of CSF obtained from 
RTT patients, where a decreased level of KCC2 expression was found (Duarte et al., 2013). More 
recently, deficits in KCC2 expression have been found in human progenitor cells from RTT patients 
(Tang et al., 2016) and in a mouse model of RTT (Banerjee et al., 2016). Interestingly, IGF1 treatment 
ameliorated the severity of the syndrome  both in RTT mouse models (Castro et al., 2014; Tropea et al., 
2009) and in  RTT patients (Khwaja et al., 2014; Pini et al., 2016), thus suggesting its implementation in 
the treatment of NDs (Bou Khalil, 2017). Nevertheless, further investigation of the NKCC1/KCC2 ratio 
and its consequence on GABA signaling are needed to better clarify the role of the two CCCs in the 
pathogenesis of RTT and their possible involvement as therapeutic targets.  
3.4. Fragile X syndrome  
Fragile X syndrome (FXS) is a genetic disorder caused by mutations in the X-linked FMR1 gene 
encoding for Fragile X mental retardation protein (FRMP). FRMP is a regulator of the translation of 
several mRNAs. FXS individuals show cognitive deficits, autistic behavior, hypersensitivity to sensory 
stimuli and comorbidity with epilepsy (Morel et al., 2018). These symptoms led researchers to 
hypothesize an excitatory/inhibitory imbalance, as previously observed in ASD and epilepsy. In 
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particular, driven by the positive outcome of the earlier pilot study on autistic patients (Lemonnier et al., 
2012), the same authors treated a FXS child with bumetanide (Lemonnier et al., 2013). Interestingly, 
bumetanide administration resulted in the amelioration of the score of each of the 5 clinical tests 
performed to probe autistic core symptoms (Lemonnier et al., 2013), opening the route to larger clinical 
trials. In agreement with the clinical study, FXS mice showed a delay in the developmental switch of 
GABA polarity from depolarizing to hyperpolarizing, due to increased expression of NKCC1 (He et al., 
2014). The same year, Tyzio and colleagues found increased Cl
-
 concentrations in hippocampal slices 
from FXS mice at P15 and P30 due to a decreased level of KCC2. Fetal treatment with bumetanide right 
before birth was able to recover the intracellular Cl
-
 concentration, GABAergic transmission and the 
behavioral features related to autism later in life (Eftekhari, Shahrokhi, et al., 2014; Tyzio et al., 2014). 
Recently, treatment of FXS mice with bumetanide during the critical period of somatosensory cortex 
plasticity rectified GABA polarity and synaptic plasticity and allowed long-lasting restoration of proper 
somatosensory-circuit formation (He et al., 2018). Moreover, a recent study found that bumetanide 
treatment by itself was insufficient to completely rescue social impairment in the automated tube test in 
FXS mice, suggesting the need for a combination therapy (Zeidler et al., 2017). Nevertheless, in the same 
study, the combination of the genetic reduction of mGluR5 expression together with bumetanide 
treatment worsened social impairment, indicating that the combination therapy needs to be better 
investigated in terms of drug type, targeting pathway and time window of administration (Zeidler et al., 
2017). Although there are only a few studies in animal models and in humans, the abovementioned 
evidence supports the involvement of the NKCC1/KCC2 imbalance in the pathogenesis of FXS syndrome 
and their modulation as a possible therapeutic strategy.  
3.5. Schizophrenia 
Schizophrenia is a neurodevelopmental disorder characterized by psychosis and cognitive impairments, 
leading to disability and premature mortality (D. A. Lewis, 2012). In particular, the clinical 
manifestations can be divided into three categories: positive symptoms (e.g., hallucinations), negative 
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symptoms (e.g., depression and apathy) and cognitive symptoms (D. A. Lewis, 2012). The etiology of 
schizophrenia is still under investigation, but a large body of literature agrees on the contribution of both 
genetic and environmental factors. GABAergic transmission seems again to play an important role in the 
pathogenesis of this ND (Balu & Coyle, 2011). In particular, the first pieces of evidence of impaired Cl
-
 
homeostasis in schizophrenia came from a study on the prefrontal cortex (and later the hippocampus) of 
schizophrenic patients, where NKCC1 expression was increased (Dean et al., 2007; Hyde et al., 2011). A 
few years later, alterations in SLC12A2 and SLC12A5 genes, encoding for NKCC1 and KCC2, 
respectively, were indicated as susceptibility genes for schizophrenia development in patients (J. Y. Kim 
et al., 2012; Merner et al., 2015; Merner et al., 2016; Potkin et al., 2009). Furthermore, increased 
expression of two kinases regulating NKCC1 and KCC2 activity, OXSR1 and WNK3, was found in the 
prefrontal cortex of schizophrenic subjects, indicating a possible increase in NKCC1 activity and a 
decrease in KCC2 function in schizophrenic patients (Arion & Lewis, 2011). In addition, an altered 
NKCC1/KCC2 ratio was described in two different mouse models of schizophrenia (Larimore et al., 
2017; Yang et al., 2015). Finally, an interplay between NKCC1 and the protein Disrupted in 
schizophrenia 1 (DISC1, an intrinsic regulator of neurogenesis implicated in schizophrenia) has been 
demonstrated to be fundamental for the regulation of the dendritic development of newborn neurons 
during adult neurogenesis in the mouse hippocampus (J. Y. Kim et al., 2012), suggesting possible 
involvement of NKCC1 in the pathogenic mechanisms underlying schizophrenia. 
Of note, in vitro evidence from Amin and coworkers revealed an imbalance in NKCC1 and KCC2 
expression also in DiGeorge Syndrome (a condition conferring high risk of schizophrenia), which caused 
hyperexcitability of the network recovered by bumetanide application to the neuronal culture (Amin et al., 
2017).  
Bumetanide treatment in schizophrenic patients reduced the severity of the symptoms and hallucinations 
(Lemonnier et al., 2016; Rahmanzadeh, Eftekhari, et al., 2017), without ameliorating the total score of the 
general positive and negative syndrome scale (PANSS) and the brief psychiatric rating scale (BPRS) 
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(Rahmanzadeh, Shahbazi, et al., 2017). Interestingly, intranasal administration of oxytocin reduced the 
severity of symptoms in schizophrenic patients in several studies (Brambilla et al., 2016; Davis et al., 
2014; Davis et al., 2013; Feifel et al., 2012; Feifel et al., 2010; Fischer-Shofty et al., 2013; Gibson et al., 
2014; Goldman et al., 2011; Lee et al., 2013; Modabbernia et al., 2013; Ota et al., 2018; Pedersen et al., 
2011; Shin et al., 2015; Woolley et al., 2017; Woolley et al., 2014), but see (Cacciotti-Saija et al., 2015; 
Caravaggio et al., 2017; Dagani et al., 2016; Horta de Macedo et al., 2014; Jarskog et al., 2017). In light 
of the ability of oxytocin to regulate GABA signaling in fetal and newborn rodents (Ben-Ari, 2018; 
Eftekhari, Shahrokhi, et al., 2014; Khazipov et al., 2008; Leonzino et al., 2016; Tyzio et al., 2006; Tyzio 
et al., 2014), it is tempting to hypothesize that oxytocin exerts its therapeutic effect on schizophrenic 
patients also by regulating CCCs. A deeper investigation of the molecular mechanisms underlying the 
possible relation between the oxytocin system and CCCs could open new avenues for the treatment of 
schizophrenia and other NDs. 
3.6. Tuberous Sclerosis Complex 
Tuberous sclerosis complex (TSC) is a multiorgan genetic disorder caused by loss of function mutations 
of the TSC1 or TSC2 genes (van Slegtenhorst et al., 1997). This pathology is characterized by the 
presence of cortical tubers (i.e., dysplastic lesions), source of focal epilepsy, autistic behaviors and 
intellectual disability. Given the imbalance of the NKCC1/KCC2 ratio in epilepsy (Schulte et al., 2018), 
the investigation of CCCs in tuberous sclerosis has gained interest. TSC patients present an increased 
NKCC1/KCC2 ratio in extracts from cortical tubers (Ruffolo et al., 2016; Talos et al., 2012). An altered 
GABA reversal potential was also described in the cortical tissues (Ruffolo et al., 2016). Altogether, these 
studies suggest a possible involvement of NKCC1/KCC2 imbalance in the pathogenesis of TSC in 
patients. Nevertheless, a better investigation of both the pathogenic mechanisms and possible therapies 




3.7. Traumatic brain injury  
Traumatic brain injury (TBI) is caused by an injury to the brain due to external objects or forces. When 
TBI occurs in early childhood, the cortical and subcortical lesions lead to altered neurodevelopmental 
processes and consequent cognitive defects persisting for the lifetime of the individual (Bonnier et al., 
2007; Jonsson et al., 2013; Keenan et al., 2007). The neurodevelopmental damages occurring after a TBI 
are the result of a cascade of events, called secondary brain injury, including damage of the blood-brain 
barrier, inflammation, excitotoxicity, edema, ischemia and neuronal damage (e.g., excitotoxicity, aberrant 
ionic homeostasis, axonal disconnection and death; (Ghajar, 2000; Park et al., 2008). One of the 
mechanisms underlying this cascade of events is possibly an imbalance of NKCC1 and KCC2 expression. 
Indeed, three independent studies found that NKCC1 was upregulated in the hippocampus and choroid 
plexus of traumatic brain injury rat models and that bumetanide administration decreased the 
inflammatory response and neuronal damage (Lu et al., 2008; Lu et al., 2006; Lu et al., 2007). Then, other 
studies confirmed the fundamental role of NKCC1 in TBI-induced rodent hippocampal aberrant 
neurogenesis (Lu et al., 2015), neuronal and astrocytic apoptosis (Hui et al., 2016; M. Zhang et al., 2017), 
cerebral edema (Lu et al., 2017; M. Zhang et al., 2016),  seizures (Liang & Huang, 2017; F. Wang et al., 
2017) BBB disruption (J. Zhang et al., 2017) and microvascular failure (Simard et al., 2010). Finally, a 
recent work described decreased KCC2 expression in the rat parietal cortex after TBI, which was rescued 
by melatonin administration leading to amelioration of neural apoptosis and brain edema (Wu, Shao, et 
al., 2016). The deep understanding of the involvement of both NKCC1 and KCC2 in the secondary brain 
injury upon TBI suggests timely pharmacological interventions to prevent the consequent 
neurodevelopmental alterations observed in TBI children.  
3.8. Glioma 
Gliomas are brain tumors derived from glial cells and are the most frequent pediatric brain tumors. Given 
their unique properties in comparison to those affect the adults, pediatric gliomas can be considered to be 
neurodevelopmental disorders (Baker et al., 2016). They will thus be discussed in this section. Among 
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pediatric gliomas, there is wide heterogeneity from histopathological and therapeutic standpoints. There 
are treatable low-grade tumors and incurable or fatal high-grade tumors. The severity level of glioma and 
the transition from low-grade to high-grade tumors is generally linked with the ability to migrate and 
invade other areas. The invasion phenomena have been widely studied in recent years to unravel their 
underlying mechanisms and find possible pharmacological targets. Among the mechanisms involved, 
NKCC1 and other transporters and channels play a role in tumor metastasis (Sontheimer, 2008). 
Accordingly, bumetanide administration reduced glioma invasion in mice (Haas & Sontheimer, 2010). 
Further studies both in primary patient-derived glioblastoma cells in vitro, and in mice in vivo, found that 
the involvement of NKCC1 in glioma cell migration was mediated by modulation of the cytoskeleton and 
regulation of cell volume (Garzon-Muvdi et al., 2012; Schiapparelli et al., 2017), opening the possibility 
of NKCC1 as a specific therapeutic target to decrease cell invasion in pediatric glioma patients.  
 
4. Chloride transporters in Down syndrome 
Down syndrome (DS) is caused by the triplication of human chromosome 21 (Hsa21) and it is one of the 
most common genetic causes of intellectual disability and congenital birth defects. Many health issues 
characterize persons with DS (Antonarakis & Epstein, 2006; Desai, 1997; Nadel, 2003; Parker et al., 
2010), with almost all individuals presenting with cognitive deficits (Dierssen, 2012; Edgin et al., 2012; 
Pennington et al., 2003; Vicari et al., 2013). 
Several studies investigated possible mechanisms involved in cognitive impairment, taking advantage of 
diverse murine genetic models of DS (Dierssen, 2012). The Ts65Dn mouse (Reeves et al., 1995) is the 
most characterized and widely used. These mice are characterized by the presence of an extra 
chromosome derived from mouse chromosome 16, representing the long arm of human chromosome 21, 
fused to the centromere of the murine chromosome 17 (Antonarakis et al., 2004). Interestingly, Ts65Dn 
mice recapitulate many features of DS. In particular, these mice show impairment in neuronal 
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development (Belichenko et al., 2004; Chakrabarti et al., 2010; Chakrabarti et al., 2007; Contestabile et 
al., 2010; Contestabile et al., 2007), defects of synaptic plasticity (Contestabile et al., 2013; Costa & 
Grybko, 2005; Kleschevnikov et al., 2004; Siarey et al., 1999; Siarey et al., 1997), impaired 
hippocampus-dependent memory functions (Contestabile et al., 2013; Costa et al., 2008; Fernandez et al., 
2007; Reeves et al., 1995), hyperactivity (Escorihuela et al., 1995; Reeves et al., 1995; Sago et al., 2000) 
and sleep disorders (Colas et al., 2008; Das et al., 2015; Stewart et al., 2007).  
 
4.1. Down Syndrome and GABAergic Transmission 
The first lines of evidence regarding the involvement of defective GABAergic transmission in DS found 
an increased number of GABAergic interneurons in the cortex and hippocampus of adult and adolescent 
Ts65Dn mice, respectively (Chakrabarti et al., 2010; Perez-Cremades et al., 2010). These alterations were 
accompanied by an increase in spontaneous GABAergic postsynaptic events in CA1 pyramidal neurons 
of adult Ts65Dn mice (Chakrabarti et al., 2010). Interestingly, subsequent studies by electrophysiological 
recordings of spontaneous, miniature and evoked GABAergic postsynaptic currents, and release 
probability as well as immunohistochemical and electron microscopy studies on the number/density of the 
GABAergic synapses and their locations provided seemingly contrasting and often inconsistent results, 
depending on the parameters analyzed, hippocampal subregion and age of the animals (P. V. Belichenko 
et al., 2009; Belichenko et al., 2004; Best et al., 2012; Chakrabarti et al., 2010; Garcia-Cerro et al., 2014; 
Hanson et al., 2007; Hernandez-Gonzalez et al., 2015; Hernandez et al., 2012; A. M. Kleschevnikov, P. 
V. Belichenko, J. Gall, et al., 2012; Kurt et al., 2000; Kurt et al., 2004; Martinez-Cue et al., 2013; Mitra et 
al., 2012; Mojabi et al., 2016; Stagni et al., 2013). Moreover, studies of DS autoptic brain samples and 
analysis of cortical neuronal progenitors obtained from DS individuals have shown a general reduction in 
the GABAergic system at various levels (Bhattacharyya et al., 2009; Kobayashi et al., 1990; Ross et al., 
1984), in seemingly inconsistence with the first evidence describing increased GABAergic transmission 




Thus, the evidence in Ts65Dn mice and brain samples taken altogether suggests that, besides an increased 
number of GABAergic interneurons, hippocampal subregion and age-dependent differences, 
compensatory mechanisms and a general increase in the excitability of the interneurons may be present in 
DS (Contestabile et al., 2017).  
Interestingly, further studies demonstrated that the altered GABAergic transmission affected synaptic 
plasticity in DS mice, experimentally measured with  long-term potentiation (LTP) protocols in acute 
brain slices of adult Ts65Dn mice (N. P. Belichenko et al., 2009; Belichenko et al., 2015; Belichenko et 
al., 2007; Costa & Grybko, 2005; Fernandez et al., 2007; A. M. Kleschevnikov, P. V. Belichenko, M. 
Faizi, et al., 2012; Kleschevnikov et al., 2004). 
Given that several pieces of evidence suggested that the cognitive deficits and abnormalities in synaptic 
plasticity observed in Ts65Dn mice derive, at least in part, from an excess of GABAA-mediated 
neurotransmission in the hippocampal circuitry, diverse studies evaluated GABAA receptors as a possible 
therapeutic target to rescue cognitive impairment in DS. For 10 years, numerous independent groups 
tested GABAA receptor inhibitors targeting diverse subunits and consistently found a rescue in LTP and 
hippocampal cognitive abilities in Ts65Dn mice (Braudeau, Dauphinot, et al., 2011; Braudeau, Delatour, 
et al., 2011; Fernandez et al., 2007; Martinez-Cue et al., 2014; Martinez-Cue et al., 2013; Mohler, 2012; 
Potier et al., 2014; Rueda et al., 2008). Similar results were obtained by treating Ts65Dn animals with 
fluoxetine, an inhibitor of serotonin reuptake ((Begenisic et al., 2014; Bianchi et al., 2010; Guidi et al., 
2014; Stagni et al., 2015), but see (Heinen et al., 2012)) or exposing the Ts65Dn animals to an enriched 
environment  (Begenisic et al., 2015; Begenisic et al., 2011; Martinez-Cue et al., 2002; Martinez-Cue et 
al., 2005). Since both fluoxetine and exposure to an enriched environment reduced GABAergic signaling 
(Baroncelli et al., 2010; Begenisic et al., 2014; Begenisic et al., 2015; Begenisic et al., 2011; Caiati & 
Cherubini, 2013; Maya Vetencourt et al., 2008; Mendez et al., 2012; Sale et al., 2007), it is possible that 
the effects on Ts65Dn mice may be due, at least in part, to modulation of GABAergic transmission, as in 




These lines of evidence reinforce the hypothesis of a causal link between the increased GABAergic 
transmission, synaptic plasticity abnormalities and cognitive deficits of DS mice (Chakrabarti et al., 2010; 
Kleschevnikov et al., 2004) and highlight GABAergic transmission as a possible therapeutic target in DS. 
On the other hand, both individuals with DS and DS mouse models show an increased susceptibility to 
seizures (Arya et al., 2011; Gholipour et al., 2017; Goldberg-Stern et al., 2001; Lott, 2012; Lott & 
Dierssen, 2010; Rissman & Mobley, 2011; Robertson et al., 2015; Smigielska-Kuzia et al., 2009; 
Stafstrom et al., 1991; Westmark et al., 2010) and hyperactivity (Deidda, Parrini, et al., 2015; Escorihuela 
et al., 1995; J. F. Moss, 2017; Pueschel et al., 1991; Reeves et al., 1995; Sago et al., 2000), and 
individuals with DS often show anxiety traits (Dekker et al., 2018; Haddad et al., 2018; Vicari et al., 
2013), pointing to excess excitation rather than inhibition in DS. 
 
4.2. NKCC1 is Implicated in Depolarizing GABAAR Signaling in Down Syndrome 
In 2015, Deidda and colleagues proposed a new perspective about GABAAR transmission in DS (Deidda, 
Parrini, et al., 2015). In their work, the efficacy and polarity of GABAAR signaling were investigated in 
adult Ts65Dn mice. Surprisingly, they found that GABAergic transmission was depolarizing and mostly 
excitatory rather than hyperpolarizing and inhibitory in adult DS mice. In particular, they described an 
increase in spike frequency in Ts65Dn hippocampal and neocortex acute slices in comparison to wild type 
(WT), both in baseline conditions and upon application of GABA. Accordingly, blockade of endogenous 
GABAA signaling by the application of the GABAAR antagonist bicuculline resulted in a reduction in the 
spike frequency in neurons from Ts65Dn brain slices. 
 
The excitatory action of GABA in Ts65Dn brain slices was accompanied by a shift ECl to more positive 
potentials. Indeed, taking advantage of the gramicidin-perforated patch clamp, a technique that allows 
maintenance of the endogenous intracellular Cl
-
 concentration, they observed that Ts65Dn neurons 
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exhibited a less negative ECl (-58 mV) in comparison to WT neurons (-66 mV). The use of gramicidin-
perforated patch-clamp was key, considering that another study conducted to investigate ECl in Ts65Dn 
mice by whole-cell patch-clamp did not detect these differences (A. M. Kleschevnikov, P. V. Belichenko, 
J. Gall, et al., 2012). Of note, an ECl value above the membrane resting potential suggests an outward Cl
-
 
current. This was indeed described by Deidda and colleagues by Cl
-
 imaging in CA1 neurons from 
Ts65Dn acute brain slice. 
  
Interestingly, the same study found that the defective GABAergic signaling was due to an increased 
expression of NKCC1 protein (Figure 8), which they found in the entire hippocampus, the CA3-CA1 
subregion and cortices of adult Ts65Dn mice compared to WT littermates. Interestingly, Deidda and 
coworkers found increased NKCC1 expression also in hippocampi from DS individuals, providing a 
parallel between the animal model and humans. Conversely, no changes in KCC2 protein expression both 
in Ts65Dn mice and DS individuals were detected. Notably, the authors did not find a significant increase 
in NKCC1 mRNA in adult Ts65Dn mice. 
 
Figure 8. Representation of the different CCCs expression in WT adult (left) and in Ts65Dn adult (right) neurons. Left: In the 
adulthood the high KCC2 expression determine a low Cl-  concentration inside the cell. When GABAAR opens, the  Cl
-  influx in 
the cell determine the neuron hyperpolarization. Right: The upregulation of NKCC1 in Ts65Dn neurons leads to an high Cl- 




4.3. Bumetanide treatment rescues the altered GABAergic transmission, synaptic 
plasticity and cognitive deficits in Ts65Dn Mice  
Considering that the increased expression of NKCC1 is the possible cause of the aberrant GABAergic 
transmission in Ts65Dn mice, Deidda and colleagues evaluated NKCC1 inhibition by bumetanide as a 
potential therapeutic strategy. Bath application of bumetanide was able to rescue ECl, with a reduction of 
spontaneous spiking activity and a decrease in the GABA-induced spike frequency in hippocampal acute 
slices of adult Ts65Dn mice. Conversely, there was no significant effect of bumetanide application in WT 
mice, confirming that the shift of ECl was responsible for depolarizing GABAAR signaling in adult 
Ts65Dn mice (Figure 9, left). 
 
Moreover, bumetanide bath application to acute brain slices was able to recover the hippocampal CA1-
CA3 LTP to WT levels, with no effect on the LTP in WT mice. Finally, Deidda and colleagues tested 
Ts65Dn mice and their WT littermates in three independent behavioral tasks to assess hippocampus-
dependent long-term explicit memory after either an acute (1 time only), subchronic (1 week) or a chronic 
(4 weeks) systemic (intraperitoneal) treatment with bumetanide. Interestingly, they showed that all three 
treatments with bumetanide were able to fully recover the poor associative memory of Ts65Dn mice in 
the contextual fear conditioning test. Moreover, bumetanide was able to rescue the performance of 
Ts65Dn mice to the level of WT mice in the object-location test, showing a full recovery of spatial-
memory performance. Finally, bumetanide administration was also able to rescue the novel-
discrimination memory of Ts65Dn mice in the novel object recognition test (Deidda, Parrini, et al., 2015) 




Figure 9. NKCC1 inhibition by bumetanide rescued Cl- homeostasis, hyperpolarizing GABAergic transmission (left) and 
cognitive and memory deficits in Ts65Dn adult mice in three different tasks (right). 
 
 
Notably, bumetanide exerted acute activity on NKCC1 and it did not provide long-lasting effects. Indeed, 
a drug withdrawal experimental protocol (i.e., a week of bumetanide washout after a four-week treatment) 
completely abolished the rescue observed in both LTP and behavioral tasks, indicating the requirement 
for chronic treatment (Deidda, Parrini, et al., 2015). 
 
5. Chloride transporters in other neurological disorders 
Recent lines of evidence suggest that an imbalance in NKCC1/KCC2 ratio is involved also in a number of 
neurological disorders other than NDs including Parkinson disease, Huntington disease, stroke and 
cerebral edema, peripheral nerve injury and neuropathic pain. As for the aforementioned NDs, restoration 
of physiological intracellular Cl
-
 concentration by pharmacological intervention aimed at inhibiting 
NKCC1 or enhancing KCC2 activity has led to positive outcomes in rodent models and patients with 
these conditions. Below is a brief description of recent findings showing how an altered NKCC1/KCC2 






5.1. Parkinson Disease  
Parkinson Disease (PD) is a neurodegenerative disorder characterized by severe motor deficits associated 
with loss of dopaminergic neurons in substantia nigra pars compacta, alterations in neurotransmission, , 
and inflammation (Kaur et al., 2018). Although the pathological mechanism underlying PD are still not 
completely clarified, alterations in GABAergic transmission seem to play a pivotal role (Blaszczyk, 
2016). For instance, aberrant, giant GABAergic currents have been found in two rodent models of PD 
(Dehorter et al., 2009; Dehorter, Lozovaya, et al., 2012) and they are blocked by procedures which 
attenuate the PD symptoms in humans (e.g. l-DOPA). This suggest that a blocking of the giant 
GABAergic currents  could provide a new therapeutic strategy (Damier et al., 2016). Thus, in light of the 
previous results on the use of bumetanide in seizures and autism which is able to restore the 
hyperpolarizing GABA, Damier and colleagues in 2016 tested bumetanide in four PD patients (Damier et 
al., 2016). Interestingly, they found that the drug was able to ameliorate the motor symptoms in all four 
patients and the gait and freezing in two of them (Damier et al., 2016). Accordingly, a recent study 
showed that bumetanide was able to recover the altered GABAergic transmission and to attenuate the 
motor deficits in a PD mouse model (Lozovaya et al., 2018). Although bumetanide showed positive 
results in both the studies, further investigation is required to assess the direct involvement of the CCCs in 
this disorder. 
  
5.2. Huntington disease 
Huntington disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of 
the trinucleotide CAG beyond 35 repeats in the huntingtin gene. The disease is characterized by 
involuntary movements, cognitive impairment and behavioral changes associated with degeneration of 
neurons in the striatum and in the cortex (Caron et al., 2018). Recent evidence indicates that an altered 
GABA signaling may underlie HD pathogenesis. In particular, HD mice showed altered expression of 
GABAAR and a reduced level of both KCC2 transcript and protein (Hsu et al., 2017), resulted in 
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depolarized ECl in HD mice. Interestingly, bumetanide administration rescued physiological GABAergic 
transmission and hippocampal-dependent learning and memory deficits (Dargaei et al., 2018) in the HD 
mice. A deeper investigation of the molecular mechanisms underlying the alteration of CCCs both in 





5.3. Stroke and cerebral edema  
Stroke is a condition characterized by poor blood flow into the brain, causing cell death. Strokes are 
classified in two main groups: hemorrhagic and ischemic. The latter group accounts for approximately 
80% of the strokes (Donnan et al., 2008). In particular, ischemic strokes are caused by a reduction of the 
blood flow usually due to arterial occlusions. Given that brain metabolism is based almost exclusively on 
the glucose delivered by the blood, a reduction of blood flow rapidly causes  metabolism failure and 
consequent tissue damage (Kahle, Simard, et al., 2009). Specifically, the lack of energy to maintain 
proper cell volume leads to cell swelling. This, causes ion imbalance, generating disruption of the BBB 
and trans-endothelial passage of fluid in the extracellular space. This fluid accumulation in the 
intracellular and extracellular spaces, even worsened when the cerebral flow is reestablished, causes the 
formation of cerebral edema which is the major cause of mortality following stroke (Kahle, Simard, et al., 
2009). The first evidence of the involvement of NKCC1 in cerebral edema came from two studies in the 
early 2000s, where NKCC1 protein was found upregulated and phosphorylated in the brain of a rat model 
of focal cerebral ischemia/reperfusion, indicating high activation of this transporter (Yan et al., 2003; Yan 
et al., 2001). Interestingly, inhibition of NKCC1 by brain perfusion of bumetanide through microdialysis 
attenuated edema and neuronal death (Yan et al., 2003; Yan et al., 2001). Accordingly, NKCC1 KO mice 
showed less white and gray matter damage after focal brain ischemia (Chen et al., 2005). Moreover, 
bumetanide administration before middle cerebral artery occlusion in a rat model of stroke, attenuated 
edema formation by inhibiting the NKCC1 located in luminal part of the BBB (Foroutan et al., 2005; 
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O'Donnell et al., 2006; O'Donnell et al., 2004). There, NKCC1 is over-expressed and over-active possibly 
due to the activation of the MAP kinases p38 JNK, ERK1/2 and AMPK (Wallace et al., 2011; Wallace et 
al., 2012; Yuen et al., 2014). In addition, the combination therapy of bumetanide and glibenclamide (i.e. 
an inhibitor of the channel SUR1/TRPM4 critical mediator of cerebral edema), was suggested to obtain a 
synergic action by trying to optimize the tissue preservation and the vascular circuit (Simard et al., 2010; 
Walcott et al., 2012). Furthermore, a recent study demonstrated that bumetanide treatment increased 
neurogenesis and behavioral recovery in rats after experimentally induced stroke (Xu et al., 2017). 
Interestingly, also the inhibition of WNK3 kinase signaling in WNK3 KO mice, by reducing NKCC1 
phosphorylation and expression, decreases cerebral edema and improves neurological recovery after 
ischemic stroke (G. Begum et al., 2015). Finally, also in diabetes-induced-stroke associated with 
hyperglycemia and in diabetic ketoacidosis, NKCC1 has been demonstrated to be involved in edema 
formation in rat models and again bumetanide administration was able to reduce the edema (Glaser et al., 
2010; Lam et al., 2005; Yuen et al., 2008; Yuen et al., 2014).  
 
5.4. Neuropathic pain and peripheral nerve injury 
Neuropathic pain is a condition caused by damage to the central or peripheral nervous system and it is 
characterized by exaggerated pain sensation called hyperalgesia, pain in response to non-noxious stimuli 
called allodynia and abnormal sensations called dysesthesia.  The first evidence of the involvement of the 
CCCs in neuropathic pain, came from early 2000s when an increased expression of NKCC1 and KCC2 
was observed in dorsal root ganglia and spinal sensory neurons in an acute arthritis model of neuropathic 
pain, while in chronic arthritis only NKCC1 was found increased (Morales-Aza et al., 2004). 
Accordingly, bumetanide and furosemide showed an anti-nociceptive action in formalin-induce 
nociception in rats (Granados-Soto et al., 2005). Then, other studies further investigated the involvement 
of the two CCCs, finding seemingly contrasting results in diverse rodent models. For instance, it is 
transiently phosphorylated, but not up-regulated in mouse models of mechanical hyperalgesia induced by 
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capsaicin (Galan & Cervero, 2005). Accordingly, bumetanide administration reduced allodynia and 
hyperalgesia in capsaicin-treated rats (Valencia-de Ita et al., 2006). Conversely, Nomura and colleagues 
found a decreased KCC2 expression in formalin-induced acute nociception in rats indicating that KCC2 -
rather than NKCC1- is involved in the first phases of hyperalgesia (Nomura et al., 2006). Accordingly, 
spinal cord injection of KCC2 antisense oligonucleotide in WT rats causes behavioral hypersensitivity 
comparable to hyperalgesia by decreasing KCC2 expression (W. Zhang et al., 2008). 
Interestingly, different studies found increased expression of NKCC1 and a decreased expression of 
KCC2 in rodent models of neuropathic pain following spinal cord and peripheral nerve injury. Notably, 
bumetanide administration showed an anti-hyperalgesic action in most of the above studies (Cramer et al., 
2008; Hasbargen et al., 2010; Lopez-Alvarez et al., 2015; Modol et al., 2014; Wei et al., 2013). 
Nevertheless, NKCC1 activation is required for the regeneration of the injured peripheral nerves (Modol 
et al., 2015; Pieraut et al., 2007), thus complicating the scenario of a possible therapeutic intervention. 
Moreover, in a recent work, Castro and colleagues found a transient and small change in ECl in mice with 
chronic injury of the trigeminal nerve, -a model of neuropathic pain- suggesting that the Cl
-
 imbalance 
may not be significantly involved in the mechanism underlying chronic pain. Hence, although a number 
of studies indicated an altered NKCC1/KCC2 ratio as a possible cause of the decrease in inhibitory tone 
implicated in neuropathic pain, further investigations are required to better elucidate the mechanism 
underlying the CCCs expression both in neuropathic pain and in nerve regeneration and their targeting as 
a possible therapeutic strategy. 
 
6.   Further considerations on Bumetanide  
Bumetanide (chemically 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; Figure 10), is a loop 
diuretic and it exerts this action by blocking NKCC2 in the ascending loop of Henle in the kidney. 
Bumetanide was developed in the ‘60s  (Asbury et al., 1972; Ostergaard et al., 1972) and nowadays is 
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indicated for the treatment of edemas caused by congestive heart failure, acute pulmonary congestion, 
hepatic disease and renal disease (Flamenbaum & Friedman, 1982; Ward & Heel, 1984).  
 
Figure 10: Structure of Bumetanide.  
 
As discussed above, a fast-increasing number of recent studies have showed that bumetanide is able to 
recover several pathological phenotypes both in rodent models of brain disorders and in patients. This 
highlights the tremendous potential for repurposing (Strittmatter, 2014) of bumetanide in the treatment of 
a number of neurodevelopmental/neurological disorders. Nevertheless, there are still some open issues, 
which prevent bumetanide to become a solid therapeutic strategy for brain disorders.  
First, being a potent diuretic, bumetanide causes hypokalemia, hypochloremia, metabolic alkalosis, 
hyperuricemia, and prerenal azotemia (Flamenbaum & Friedman, 1982) and indeed for instance in Italy it 
is currently only used in hospitals. Thus, the use of a strong diuretic to treat patients with severe 
behavioral impairments as in NDs or other neurological conditions may seriously jeopardize drug 
compliance during chronic, daily treatment, as for example required in a DS mouse model (Deidda, 
Parrini, et al., 2015). Moreover, NKCC2 is also expressed in vasopressinergic and oxytocinergic neurons 
in the hypothalamo-neurohypophyseal system and in the vestibular system, increasing the potential side 
effects of a chronic bumetanide treatment. In particular, bumetanide’s negative effects on the auditory 
system have proved critical for the treatment of infants. Indeed, one clinical trial for the repurposing of 
bumetanide for the treatment of acute neonatal encephalopathy seizures was suspended due to induced 
deafness in some treated subjects (Ben-Ari et al., 2016). Second, a number of studies highlighted 
bumetanide’s poor blood-brain barrier penetration (Brandt et al., 2010; Cleary et al., 2013; Puskarjov, 
Kahle, et al., 2014; Tollner, Brandt, Romermann, et al., 2015; Topfer et al., 2014) and recent 
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investigations considered bumetanide’s low levels in the brain after systemic administration as 
incompatible with NKCC1 inhibition, thus questioning the brain expressed-NKCC1 as the target of 
bumetanide in ND (Romermann et al., 2017; S. Wang et al., 2015).  
Thus, although bumetanide has shown positive outcomes in the treatment of core symptoms of a number 
of neurological disorders, the effectiveness of NKCC1 as a molecular target for these conditions, and the 
mechanism of bumetanide action need to be further investigated and confirmed. This would be a pre-
requisite for any drug discovery effort aimed at finding new NKCC1 inhibitors devoid of all of the 
bumetanide’s shortcomings.  
7. NKCC1 is a valuable target to rescue cognitive impairment in DS 
Although preclinical studies on animal models and clinical trials as well as case studies indicate positive 
outcomes of bumetanide treatments on several brain disorders, so far its putative mechanism/target has 
not yet been clarified. Other members of the Cancedda laboratory have tried to address this issue at least 
for DS. In particular, to support previous finding on the positive effect of chronic bumetanide on 
cognitive impairment in a mouse model of DS (Deidda, Parrini, et al., 2015) and to demonstrate NKCC1 
as a potential molecular target for new therapeutic approaches members of the Cancedda laboratory 
(unpublished data)  has recently investigated the effectiveness of a RNA interference-based NKCC1 
downregulation in rescuing cognitive impairment in DS mice. In particular, they used artificial 
microRNAs, cloned into a lentiviral vector (AAV9), to knockdown (KD) NKCC1 in Ts65Dn mice. After 
confirming that NKCC1 downregulation by viral infection was able to restore the physiological Cl
- 
concentration and the inhibitory GABA transmission in cultured trisomic neurons, they have tested 
whether the specific KD of NKCC1 by a single viral injection in the hippocampus was able to rescue 
learning and memory deficits in adult Ts65Dn mice. Four weeks post injection, they found a complete 
rescue of cognitive performance of Ts65Dn mice in comparison to WT mice in four independent tests. 
Thus, although the mechanism of action of bumetanide has still not been clarified yet, these results have 
altogether clearly identified NKCC1 as potential molecular target for Down syndrome. Hence, a 
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compound which can selectively inhibit NKCC1, and thus devoid of the side effects of bumetanide, could 
represent a valuable therapeutic strategy for DS and possibly the other neurological disorders 
characterized by impaired Cl
-
 homeostasis and depolarizing GABAergic transmission.  
 
Figure 11. A) Left: schematic cartoon of the experimental protocol for viral injection to knock down NKCC1 in WT and 
Ts65Dn mice and the consequent behavioral analysis. Right: examples images of WT and Ts65Dn hippocampi  injected with 
lentiviral vector (in green) encoding for two different miRNA knocking down NKCC1 expression.  B-E ) Effect of knock down 
of NKCC1 in novel object recognition (B), object location (C), contextual fear conditioning (D) and  T- maze (E) tasks. 
Unpublished data of other members of the Cancedda laboratory. 
45 
 
Aim of the project 
 
Several lines of evidence indicate impaired Cl
-
 homeostasis by dysregulation of NKCC1/KCC2 
expression ratio or function as a potential causal mechanism underlying the phenotypic manifestation of a 
number of neurological disorders. Interestingly, many preclinical studies, clinical case studies and clinical 
trials point to a valuable therapeutic approach to restore physiological Cl
-
 homeostasis to treat neurologic 
patients with a known diuretic drug (bumetanide), which can be readily repurposed in humans. Although 
bumetanide provides an invaluable pharmacological tool for a quick assessment -directly in patients- of 
the positive effects of blocking NKCC1 activity, its extensive usage may be hampered by its diuretic and 
other side effects due to inhibition of the kidney transporter NKCC2. In particular, excessive diuresis may 
jeopardize the compliance with chronic treatment by patients with serious conditions, often characterized 
by cognitive issues as in DS and ASD. Moreover, its poor BBB penetration questioned brain-expressed 
NKCC1 as an effective target and opened debates about the real mechanism of action of bumetanide in 
neurological disorders. Nevertheless, recent findings from our lab demonstrated that specific knockdown 
of NKCC1 was able to restore physiological Cl
-
 concentration and GABAergic transmission in trisomic 
neurons in vitro, and learning and memory in the Ts65Dn mouse model of DS. These results identified 
NKCC1 as a targetable molecule for treating Down syndrome and possibly other neurological disorders 
characterized by aberrant Cl
-
 homeostasis.  
This project aims at discovering novel compounds able to modulate GABAergic activity through the 
selective inhibition of the Cl
-
 importer NKCC1, thus being devoid of unwanted diuretic and related side 








1. Setup of a functional NKCC-transporter assay: the chloride assay 
To screen in vitro the new compound efficiency in blocking NKCC1 and NKCC2, we setup a functional 
NKCC transporter assay. This is based on the detection of the variation of Cl
-
 ion concentration in the cell  
through a Cl
-
 sensitive membrane-tagged yellow fluorescent protein (mbYFPQS, Addgene). mbYFPQS 
fluorescence is inversely dependent on the concentration of Cl
-
 inside the cell. In particular, the assay 
consists of monitoring the variation of fluorescence intensity in HEK293 cells transfected with NKCC1, 
NKCC2 or the empty plasmid (as control-mock), loaded with mbYFPQS and maintained in a Cl
-
 free-
hypotonic solution. Upon application of NaCl in the bath, Cl
-
 ions enter into cells by NKCC1 and NKCC2 
transport and bind mbYFPQS, thus determining a fluorescence decrease. Therefore, in this assay, one can 
indirectly estimate Cl
-
 transporter activity by mbYFPQS fluorescence variations.  
 
First, we evaluated transfection efficiency in our experiments by assessing the expression of NKCC1 or 




Figure 12: Western blot analysis of the expression of NKCC1 (Left) and NKCC2 (right) in untransfected (mock) and NKCC1- or 
NKCC2-transfected HEK293 cells.  Transfection of NKCC1 or  NKCC2 plasmids results in a high expression of the related 




As a first step of the assay validation, we evaluated whether the transfected transporters were functionally 
active. We collected 80 secs of fluorescence baseline in cells transfected with control plasmid, NKCC1 or 
NKCC2. Upon application of 444 mM of NaCl, we assessed fluorescence intensity for another 60 secs. 
During this period, we observed a fluorescence decrease in the transfected cells in comparison to the non-
transfected ones, which is indicative of NKCC1 and NKCC2 activities (Figure 13). For the representation 
of the fluorescent traces in time (Figure 13, left), we normalized the fluorescence value for each time point 
to the average of the fluorescence value of the first 20 sec of baseline. For quantification of average effects 
as we represented by the bar plots (Figure 13, right), we expressed the decrease in fluorescence upon NaCl 




Figure 13 A) Left: example traces obtained in the chloride assay on untransfected (mock) or NKCC1- transfected HEK293 cells. 
The arrow indicates the addition of NaCl (final concentration 74 mM) used to initiate the flux of chloride. Right: quantification 
of the fluorescence decrease upon the NaCl application in the untrasfected (mock) or NKCC1-transfected HEK293 cells. B) Left: 
example traces obtained in the chloride assay on untransfected (mock) or NKCC2- transfected HEK293 cells. The arrow 
indicates the addition of NaCl (final concentration 74 mM) used to initiate the flux of chloride. Right: quantification of the 
fluorescence decrease upon the NaCl application in the untransfected (mock) or NKCC2-transfected HEK293 cells. Data 




To further validate the Cl assay in HEK293 cells, we next monitored the fluorescence in mock, NKCC1 
and NKCC2-transfected cell treated with DMSO (0.1%-1%) as control or with the known inhibitors of 
NKCC1 and NKCC2 (bumetanide and furosemide). As shown in figure 14, pre-incubation at two different 
concentrations (10 µM, 100 µM) with bumetanide or furosemide significantly reduced the decrease in 
fluorescence in mock, NKCC1- and NKCC2 -transfected cells, indicative of a reduced ion flux and thus 
transporter inhibition. Notably, the decreased fluorescence observed also in the mock-transfected cells 
treated with bumetanide and furosemide indicates that HEK293 cells express endogenous Cl
-
 transporters 
(including NKCC1 observed in western blot analysis), which are bumetanide/furosemide sensitive. Thus, 
we setup a normalization of the fluorescence values that could exclude the contribution of Cl
-
 changes 
dependent on transporters/receptors other than NKCC1 or NKCC2. In particular, we subtracted the ΔF/F0 
value obtained from mock-transfected cells (either control or treated) to the respective ΔF/F0 value obtained 
from the cells transfected with NKCC1 or NKCC2. We then presented in the figures all the data as a 





Figure 14. A) Top: example traces obtained in the chloride assay on untransfected (mock) HEK293 cells treated with DMSO as 
negative control, bumetanide (Bume) and furosemide (Furo) as positive controls. Bottom: quantification of the fluorescence 
decrease upon the NaCl application in mock-transfected HEK293 cells treated with DMSO, bumetanide and furosemide. B) Top: 
example traces obtained in the chloride assay on NKCC1-transfected HEK293 cells treated with DMSO as negative control, 
bumetanide (Bume) and furosemide (Furo) as positive controls. Bottom: quantification of the fluorescence decrease upon the 
NaCl application in NKCC1-transfected HEK293 cells treated with DMSO, bumetanide and furosemide. C) Top: example traces 
obtained in the chloride assay on NKCC2-transfected HEK293 cells treated with DMSO as negative control, bumetanide (Bume) 
and furosemide (Furo) as positive controls. Bottom: quantification of the fluorescence decrease upon the NaCl application in 
NKCC2-transfected HEK293 cells treated with DMSO, bumetanide and furosemide. Data represents mean ± sem from 5 
independent experiments. *** p<0.001 Kruskal-Wallis One Way Analysis of Variance on Ranks, Dunn’s post hoc test 
 
2. Design, synthesis and testing of novel bumetanide analogues  
To decipher among the structural and chemicophysical properties of bumetanide what the responsible for 
the inhibition of NKCC1 vs NKCC2  are, we designed and synthesized novel bumetanide analogues. This 
strategy provided information that allowed building an informative structure-activity relationship. This in 
turn, provided highlights into what is indeed essential for selective NKCC1 inhibition.  
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We developed a synthetic strategy to obtain a number of novel bumetanide analogs, which bear 
modifications at different anchor points of bumetanide’s core scaffold (Figure 15). Based on the 3-amino-4-
phenoxy-5-sulfamoil-benzoic acid core of bumetanide, we explored the implication of the substituents in 
positions R1, R3 and R5, by medicinal chemical efforts coupled with a systematic analysis of the newly 
synthesized compounds’ ability to inhibit NKCC1 or NKCC2.  We synthesized 19 new compounds analog 
to bumetanide.  
 
Figure 15. Structures of bumetanide and close analogues. Top: Schematic representation of the point of intervention in the 
bumetanide structures to synthesize 5 novel bumetanide analogues. Bottom: Structures of the five bumetanide analogues. 
ARN21902 was synthesized by substituting the acid with the ester; ARN21878, ARN22351 and ARN22381 show modification 
in the carbon chain on the amino group: ARN21878 and ARN22351 have a longer chain, ARN 22381 show a bulker chain. 
ARN22837 show dimethylation in the sulfonamide.  
 
 
Then, we tested (by the chloride assay in HEK293 cells) the inhibitory activity of the new analogues and 
compared it to that of bumetanide and furosemide (as positive controls). We normalized the data as 
described above, and expressed them as % of inhibition vs DMSO-treated cells. As shown in figure 16, 
bumetanide inhibited NKCC1 at a 58.8 ± 5.6 % and NKCC2 at 82.7 ± 20.4 % at 10 μM, and NKCC1 at 
71.7 ± 7 % and NKCC2 at 80.5 ± 9 % at 100 µM. Consistent with the literature indicating effective NKCC 
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inhibition only at high concentration (Ramsay et al., 1978), furosemide did not show a significant inhibition 
of NKCC1 or NKCC2 at 10 μM, but inhibited NKCC1 at 56.3 ± 6 % and NKCC2 at  57.2 ± 10.2 % at 100 
µM. Then, we tested the newly synthesized compounds for NKCC1 and NKCC2 inhibitory activity. 
ARN21902, which bears an ester moiety in R1, displayed a complete loss in activity against both NKCC1 
and NKCC2, indicating that the acidic group in R1 is fundamental to maintain activity against the two 
CCCs. Interestingly, the elongation of the carbon chain on the amino group in R3 determined a gain in 
selectivity toward NKCC1 compared to bumetanide. Indeed, both ARN21878 (n-hexyl chain) and 
ARN22351 (n-octyl chain) did not inhibit NKCC2 at 10 µM and inhibit NKCC2 at 61.9 ± 9,1 % 
(ARN21878) and 32.9 ± 11.55 % (ARN22351) at 100 µM, which was smaller than the 80.5 ± 9 % 
inhibition of bumetanide. Nevertheless, these compounds also showed a loss in potency against NKCC1 at 
10 µM when compared to the 58.8 ± 5.6 % of inhibition of bumetanide, but maintained a good inhibition of 
NKCC1 at 100 µM of  90 ± 9.7 % (ARN21878) and ~ 22.4 ± 4.8  % (ARN22351), when compared to the  
82.7 ± 20.4 % of inhibition of bumetanide. Conversely, preserving the C4 butyl chain length, with the 
insertion of terminal bulky 3,3-dimethylbutyl element in R3 (ARN22381) determined a loss of activity 
against NKCC1 at 10 µM, but maintained a 126 ± 6.9 % inhibition at 100 µM . When tested against 
NKCC2, ARN22381 exhibited a good inhibition both at 10 µM (48.4 ± 8.3 %) and at 100 µM (81.7 ± 
7.1%), when compared to bumetanide’s activity (82.7 ± 20.4 % at 10 µM; 80.5 ± 9 % at 100 µM). To 
investigate the role of the sulfonamide in R5, we synthesized a dimethylamino derivative (ARN23837). 
Strikingly, the switch from H-bond donor (HBD) / H-bond acceptor (HBA) of bumetanide to HBA of the 
sulfonamide of ARN23837 determined a complete loss of activity against NKCC2, still maintaining 
inhibition of NKCC1 at 100 µM  (22.4 ± 6.7 %). Nevertheless, also in this case, the new compound lost 
efficacy of inhibition when compared to bumetanide (80.5 ± 9 %).    
Thus, the synthesis and testing of the close derivatives of bumetanide allowed us to decipher some 
structural motifs which could decrease the activity against NKCC2 (i.e., elongation of the carbon chain in 
R3 and the dimethylation of the sulfonamide in R5. Nevertheless, none of the compounds exerted a 
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markedly higher NKCC2/NKCC1 selectivity, confirming data from the literature on other bumetanide 
analogues (Lykke et al., 2016).  Altogether, these data suggest a large difficulty, to develop bumetanide 
derivatives with higher selectivity for NKCC1 vs NKCC2 than bumetanide (Lykke et al., 2016). Thus, we 
decided to seek new molecular entities, structurally unrelated to bumetanide, to find novel selective 
NKCC1 inhibitors without the unwanted effect on NKCC2. In directing our search, we nevertheless took 
advantage of the knowledge acquired from the experiments on bumetanide’s analogues.  
 
Figure 16. Left: quantification of the inhibitory activity of bumetanide (Bume 10, 100 µM) and furosemide (Furo 10, 100 µM) 
as positive controls and bumetanide analogues ARN21902, 21878, 22351, 22381 and 23837 (10, 100 µM). in NKCC1-
transfected HEK293 cells. Data are presented as a percentage of the respective control DMSO. Data represents mean ± sem from 
4 independent experiments. * P<0.05, *** P<0.001  Kruskal-Wallis One Way Analysis of Variance on Ranks , Dunn’s post hoc 
test. Right: quantification of the inhibitory activity of bumetanide (Bume 10, 100 µM) and furosemide (Furo 10, 100 µM) as 
positive controls and bumetanide analogues ARN21902, 21878, 22351, 22381 and 22837 (10, 100 µM). in NKCC2-transfected 
HEK293 cells. Data are presented as a percentage of the respective control DMSO. Data represents mean ± sem from 3 
independent experiments. * P<0.05, ** P<0.01, *** P<0.001  Kruskal-Wallis One Way Analysis of Variance on Ranks , Dunn’s 
post hoc test. 
  
 
3. Identification of novel hits that selectively block NKCC1 
3.1 Screening from libraries 
Through the application of a ligand-based computational strategy, applied to bumetanide and other known 
analog compounds (i.e. furosemide, asozemide, piretanide, chlorithiazide) with activity against the target 
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protein NKCC1, we identified a few key structural and chemicophysical properties that are shared among 
bumetanide and the other compounds. In particular, we built a preliminary pharmacophore model and we 
used it as a filter for the virtual screening of the proprietary chemical collection available at the D3 
Department at IIT (Figure 17). This library contains a diverse and non-redundant set of ~15,000 molecules 
readily available for experimental testing. In a first set of experiments, we used the ligand-based to select 
165 new compounds from the IIT library, which we tested for their ability to inhibit NKCC1 in the chloride 
assay in HEK293 cells. Among these compounds, 20% showed an NKCC1 inhibition ranging between 5%-
10% at 10 µM, while the other 80% did not show any activity.  Then, starting from the chemical structure 
of the active compounds, we refined the initial pharmacophore model and we performed a second and more 
specific screening of the D3’s chemical collection, and chemical libraries from commercial vendors (Life 
chemicals and ZINC). In this second set of experiments, we selected 90 compounds (Figure 17, maroon).  
 
Figure 17.  Using the structure of bumetanide and several close analogues, we designed a pharmacophore model with the key 
geometric and physicochemical features needed for activity. This model was used for the preliminary screening of the D3 internal 
library of small molecules. After the first screening of 167 compounds, we refined the pharmacophoric model to screen chemical 
libraries from commercial vendors, from which we selected 86 compounds to be tested in vitro.  
 
Among these 90 compounds, only two showed a significant (although moderate) inhibitory activity against 
NKCC1 when tested in the Cl assay on HEK293 cells. In particular, two structurally related 2-amino-5-
nitro-benzenesulfonamide (Figure 18) derivatives diversified for the substituent on the amino group, 
emerged as promising hit compounds. ARN22393, with a n-hexyl chain on amino group and a methylated 
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sulfonamide, showed a significant inhibition of NKCC1 of  29.4 ± 2.8 % at 100 µM. ARN22394, with a 
3,3-dimethylbutyl chain on the amino group and a methylated sulfonamide, showed a significant inhibition 
of NKCC1 of 17.7 ± 3.9 % at 10 µM and of  28.6 ± 4.3 % at 100 µM. Although promising, the two 
compounds still showed low potency in NKCC1 inhibition compared to bumetanide. Thus, ARN22393 and 
ARN22394 were utilized as a starting point for the design and synthesis of new and more potent 
derivatives.  
 
Figure 18. Left : Chemical structure of the compounds ARN22393 and ARN22394 obtained from the screening of pre-existing 
compound libraries.  Right: Quantification of the inhibitory activity of bumetanide (Bume 10, 100 µM) and furosemide (Furo 10, 
100 µM) as positive controls and ARN22393(10, 100 µM)  and ARN22394 (10, 100 µM) obtained from the libraries screening  in 
NKCC1-transfected HEK293 cells. Data are presented as a percentage of the respective control DMSO. Data represents mean ± 
sem from 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001  Kruskal-Wallis One Way Analysis of Variance on Ranks 
, Dunn’s post hoc test.   
  
3.2 Synthesis of new molecular entities  
Based on the chemical core of ARN22393 and 22394, we synthesized 43 new compounds, which we 
tested in the chloride assay on HEK293 cells. Two main scaffolds were generated based on the 
substituents in position 1 of the aromatic ring: (a) a 2-amino-5-nitro-benzene-sulfonamide and (b) a 4-
amino-3-sulfamoyl-benzoic acid (Figure 18). In particular, we compared the nitro group with the more 
drug-like carboxylic acid, which we demonstrated to be fundamental for the inhibition of the CCCs, and 




Figure 19. Chemical structure of the two scaffolds based on the substituents in position 1 of the aromatic ring: (a) 2-amino-5-
nitro-benzenesulfonamide and (b) 4-amino-3-sulfamoyl-benzoic acid. From the manipulation of these two scaffolds, we 
generated 43 new compounds.  
 
Although we synthesized and tested in the Cl- assay 12 new 2-amino-5-nitro-benzenesulfonamides (a), 
none of them exhibited enhanced potency in NKCC1 inhibition in comparison to the hit compounds 
(ARN22393 and ARN22394). In addition, low solubility issues burdened the 2-amino-5-nitro-
benzenesulfonamide scaffold, and we halted the further synthetic efforts towards its investigation. 
Conversely, benzoic acid derivatives emerged as the best class in terms of potency when compared to 
nitrobenzenes. In particular, we performed numerous manipulations on this class by adding the structural 
motifs emerged from the screening of the bumetanide analogues (i.e.,the dimethylated sulfonamide and 
the n-octyl carbon chain on the amino group).  Benzoic acid derivatives bearing the n-octyl substituent 
showed enhanced potency when compared to the shorter chain derivatives. In particular, ARN22642, 
characterized by a methyl sulfonamide and an n-octyl chain on the amino group significantly inhibited 
NKCC1 of 35.4 ± 17.3 % at 100 μM, although it did not show significant activity at 10 μM (Figure 20).  
Interestingly, when this modification was combined with dimethylation of the sulfonamide, the resulting 
derivative (ARN22430) exerted high inhibition, significantly increasing the activity to 70.6 ± 9.1 % at 
100 μM, but still did not significantly inhibit NKCC1 at 10 μM (Figure 20). 
Next, we tested ARN22642 and ARN22430 for their solubility and their preliminary absorption-
distribution-metabolism-excretion (ADME) properties (Figure 20B), by assessing their half-life in mouse 
plasma and mouse liver homogenates (microsomes). We found that both compounds showed low 
solubility. Moreover, although they showed protracted half-life in mouse plasma (>60 mins), they 
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displayed very short half-life in mouse microsomes (12 mins ARN22642 and 13 mins ARN22430). To 
overcome this issue, we tried to protect the terminal methyl of the n-octyl carbon chain (the most eligible 
point of metabolism) by adding different substituents. In particular, we tested the bioisostheric 
trifluoromethyl group, which is widely used in medicinal chemistry to ameliorate properties of promising 
compounds (Studer, 2012). The resulting terminal trifluoromethylated analogue (ARN23746) showed a 
substantial improvement in solubility (> 250 μM) and a longer half-life both in mouse plasma (> 120 
mins) and in mouse microsomes (> 60 mins). Moreover, ARN23746 showed an increased potency 
displaying an NKCC1 inhibition of 37.1 ± 5 % at 10 μM, which is comparable to bumetanide’s activity of  
51 ± 4.2 % (Figure 20 D). Moreover, ARN23746 inhibited NKCC1 of 88.5 ± 11.7 % at 100 μM in 
comparison to  71 ± 6 %  inhibitory activity of  bumetanide (Figure 19 C-D). Thus, by applying the 
information collected from data derived from bumetanide’s derivatives, we found three new compounds 
(ARN22642, ARN22430, and ARN23746) able to efficiently inhibit NKCC1. We thus characterized 





Figure 20. A) Chemical structures of the compounds ARN22642, ARN22430 and ARN23746 obtained from the manipulation of 
the scaffold in Figure 18. B) Table showing the ADME  properties of ARN22642, ARN22430 and 23746. C) Examples traces 
obtained in the chloride assay on NKCC1-transfected HEK293 cells treated with DMSO as negative control, bumetanide (Bume) 
and furosemide (Furo) as positive controls, and ARN22642, ARN22430 and ARN23746 (100 μM of each compound in these 
examples). D) Quantification of the inhibitory activity of bumetanide (Bume 10, 100 µM) and furosemide (Furo 10, 100 µM) as 
positive controls and ARN22642 (10, 100 µM), ARN22430 (10, 100 µM) and ARN23746 (10, 100 µM) in NKCC1-transfected 
HEK293 cells. Data are presented as a percentage of the respective control DMSO. Data represents mean ± sem from 3 
independent experiments. *P<0.05, ** P<0.01, *** P<0.001  Kruskal-Wallis One Way Analysis of Variance on Ranks , Dunn’s 
post hoc test.   
 
4. Set up of Calcium kinetic assay and testing of the three most promising compounds  
To further confirm the activity on NKCC1 of the 3 novel molecular entities (ARN22642, ARN22430, 
ARN2376), we tested their ability to revert the depolarizing GABA signaling in young neurons, indirectly 
measured as calcium influx into the cells with an in vitro calcium kinetic assay in primary neuronal 
cultures. This assay takes advantage of the physiological, endogenous, high-expression of NKCC1 in 





channels. Thus, in immature neurons, a compound that blocks NKCC1 is predicted to inhibit Ca
2+
 
responses upon GABA application (Figure 21).  
 
Figure 21. Schematic representation of the calcium kinetic assay performed in primary neuronal cultures. Left: physiological 
high-expression of NKCC1 in immature neurons causes depolarizing GABA transmission, which activates voltage-gated Ca2+ 
channels determining a calcium influx. Right: in immature neurons, a compound that blocks NKCC1 is predicted to reduce the 
GABA depolarizing action, thus inhibiting Ca2+ responses upon GABA application. 
 
We cultured hippocampal immature neurons for 3 days in vitro (3DIV) and loaded them for 15 min with a 
calcium-sensitive dye (Fluo4, Invitrogen) in extracellular solution. Then, we treated the neurons with 
bumetanide and furosemide (as a positive control) or each of our 3 best compounds diluted in 
extracellular solution for 15 min. As a functional readout, we monitored the level of fluorescence in the 
neuronal cultures pretreated with bumetanide, furosemide or our new compounds (ARN22642, 
ARN22430, ARN2376) upon application of GABA (100 M, for 20 sec). To test for neuronal viability, 
we applied KCl (90 mM, for 40 sec) after GABA treatment. Indeed, KCl strongly depolarizes neurons 
causing high activation of voltage-gated Ca
2+
 channels in live cells, which can be taken as an indication of 
cell viability. To quantify the effect of bumetanide and our new compounds on NKCC1 inhibition, we 
thus normalized the fluorescence values upon GABA application to the fluorescence levels after KCl 
application in treated neurons. As shown in figure 22, all tested compounds significantly reduced the 
increase in fluorescence upon GABA application in comparison to DMSO-treated controls, without 
affecting the fluorescence level upon KCl application. In agreement with the chloride assay, bumetanide 
displayed an inhibition of calcium entry of  51.9 ± 2.3 % at 10 μM and  54.7 ± 2.5 % at 100 μM, and 
ARN23746 displayed an inhibition of 45.7 ± 4.3 % at 10 μM and  92.8 ± 1.9 % at 100 μM. Surprisingly, 
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in this assay, furosemide, ARN22642 and ARN22430 showed a significant activity also at 10 μM. In 
particular, furosemide showed an inhibition of calcium entry of 36.3 ± 3 % at 10 μM and  62.4 ± 2.8 % at 
100 μM, ARN22642 inhibited calcium entry of 18.6 ± 5.3% at 10 μM and  46.3 ± 3.7% at 100 μM, and 
ARN22430 inhibited calcium entry of 44.8 ± 4.1 % at 10 μM and 76 ± 8.8 % at 100 μM.    
 
Figure 22. A) Example traces obtained in the calcium kinetic assay on 3DIV neurons. The arrow indicates the addition of GABA  
(final concentration 100 µM) and KCl (90 mM) used to evaluate the cell viability (100 μM of each compound in these examples) 
B) Quantification of effect of Bumetanide (Bume 10, 100 µM), Furosemide (Furo 10, 100 µM),ARN22642, ARN22430 and 
ARN23746 (10, 100 µM)  in the calcium kinetic assay on 3 DIV neurons. Data are resented as a percentage of the control 
DMSO. Data represents mean ± sem from 3 independent experiments. ** P<0.01, *** P<0.001 Kruskal Wallis one-way 
ANOVA, Dunn’s post hoc test.   
 
Thus, although the new molecular entities were able to significantly reduce the GABA depolarizing 
signaling in young neurons, the seeming inconsistency of the activity of furosemide, ARN22642 and 
ARN22430 between the chloride assay and the calcium assay, required further investigation.   
5. Electrophysiological recordings of GABA currents  
To better clarify the high efficiency of furosemide, ARN22642 and 22430 to inhibit Ca
2+
 responses upon 
GABA application, in comparison to the moderate inhibition of NKCC1 in the chloride assay, we 
measured the ability of these compounds to inhibit GABAAR. Indeed, the inhibition in Ca
2+
 responses 
measured in the calcium assay, could be explained by a strong NKCC1 inhibition, but also by a possible 
60 
 
direct antagonism of GABAA receptors. Interestingly, it is known that furosemide, antagonizes  the  
GABAA receptor in cerebral cortex and cerebellum (Korpi et al., 1995; Korpi & Luddens, 1997; Minier & 
Sigel, 2004). Thus, we measured the amplitude of evoked GABAA currents after application of 
bumetanide (as a negative control), furosemide (as a positive control), ARN22642, ARN22430 and 
ARN23746. As concentration we chose 10 μM to detect even small inhibitory efficacy of the drugs. As 
shown in Figure 23, bumetanide and ARN23746 did not alter GABAA-current amplitude. Conversely, 
furosemide showed 19.4 ± 5 % reduction in the GABAA-current amplitude, in agreement with the 
literature. Notably, ARN22430 showed a significant inhibition of GABA current of a 20.6 ± 2.6 % and 




Figure 23: Top: Amplitude of evoked GABAA currents before (Baseline) and after 5 minutes of 10µM drug application 
(Treatment); circles connected by lines represent individual cells, Paired t-test. Bottom: Mean ± SEM of amplitude change of 
GABA-evoked currents showed in the top graphs. Drug responses were normalized to the amplitude of the GABA current before 




Taken together, these results indicate that among the ~300 compound tested, ARN23746 was the one 
showing the higher inhibition of NKCC1 in the chloride assay, which was confirmed in the calcium 
assay, and it did not show any significant inhibition of the GABAAR. Hence, we further proceeded with 
the in vitro characterization of this “lead compound”. 
6. In vitro characterization of ARN23746   
6.1 ARN23746 restores the physiological chloride concentration in Ts65Dn neurons  
As previously demonstrated by Deidda and colleagues, hippocampal Ts65Dn neurons show an increased 
intracellular Cl
-  
concentration in comparison to WT littermates, which is due to an increased expression 
of NKCC1 (Deidda, Parrini, et al., 2015). Thus, we further tested ARN23746 efficacy to block NKCC1 in 
hippocampal cultured Ts65Dn neurons where we predicted that it would restore physiological 
intracellular Cl
- 
 concentration. We prepared hippocampal neuron cultures from Ts65Dn and WT embryo 
littermates and performed the experiments at 15 DIV, when the GABA switch from depolarizing to 
hyperpolarizing has already occurred in cultures (Ganguly et al., 2001). We measured the intracellular Cl
- 
 
concentration upon treatment  with DMSO (as negative control), bumetanide and furosemide (as positive 
controls), and ARN23746. To measure intracellular Cl
- 
concentration, we took advantage of the chloride-
sensitive dye MQAE, which fluorescence is inversely correlated with the concentration of chloride. As 
shown in figure 24, we confirmed that Ts65Dn neurons are characterized by an increased intracellular Cl
-
 
level (corresponding to lower MQAE fluorescence intensity) in comparison to WT neurons. As expected, 
bumetanide and furosemide at 10 μM were able to significantly restore the intracellular Cl
- 
concentration 
to WT levels. Interestingly, also ARN23746 at 10 μM significantly restored Cl
- 
 to physiological levels, 
without significantly affecting the Cl
- 




Figure 24: Top: representative pseudo-color images (colored scale below) of the intracellular Cl- concentration measured with 
the MQAE chloride dye, in WT and Ts65Dn hippocampal neurons after treatment with DMSO (as negative control), Bumetanide 
and Furosemide (as positive controls) and ARN23746. Bottom: quantification of effect of Bumetanide (Bume 10 µM), 
Furosemide (Furo 10 µM) and ARN23746 (10 µM) in modulating intracellular chloride concentration in 15DIV cultured neurons 
from hippocampus of WT and Ts65Dn mice. Data represents mean ± sem from 3 independent experiments * P<0.05, ** P<0.01; 
Two Way Analysis of Variance, Tukey’s post hoc test.   
 
6.2 ARN23746 does not show a significant inhibition of NKCC2  
Once we validated the efficiency of ARN23746 in inhibiting NKCC1 in three independent assays, we 
investigated its activity against NKCC2. To this aim, we took advantage of the previously described 
chloride assay on HEK293 cells transfected with NKCC2. As shown in figure 25, bumetanide at 10 μM 
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significantly inhibited NKCC2to  82.7 ± 20.4 %. Conversely, ARN23746 did not show a significant 
inhibitory activity on NKCC2.   
 
Figure 25. A) Example traces obtained in the chloride assay on NKCC2-transfected HEK293 cells treated with DMSO as 
negative control, bumetanide (Bume) as positive control and ARN23746. B) Quantification of the inhibitory activity of 
bumetanide (Bume 10µM) as positive control and ARN23746 (10 µM) in NKCC2-transfected HEK293 cells. Data are resented 
as a percentage of the respective control DMSO. Data represents mean ± sem from 5 independent experiments*** P<0.001;  
Kruskal-Wallis One Way Analysis of Variance on Ranks , Dunn’s post hoc test.   
  
6.3 ARN23746 show an excellent solubility and metabolic stability in vitro  
In view of in vivo studies with systemic administration of compound ARN23746, we first evaluated some 
chemical and physical proprieties. In particular, we measured the solubility of ARN2346 in PBS at pH 
7.4. As reported in Table 1, ARN23746 showed an excellent kinetic solubility, reaching the target 
concentration of 250 μM, and its thermodynamic solubility reached a maximum concentration of 181 μM 
in PBS. Next, we tested the plasmatic stability of ARN23746 in mouse plasma. The compound 
demonstrated a long plasmatic stability with a half-life of over 120 minutes. Furthermore, to evaluate the 
metabolization of ARN23746, we assessed its stability in microsomes obtained from mouse and rat. 
ARN23746 showed excellent half-life in both species (Table 1). Moreover, ARN23746 displayed also 
protracted half-life in microsomes obtained from human liver (Table 1). Then, we explored metabolism in 
rat and human more deeply by identifying possible metabolites. Two main metabolites were detected by 
liquid chromatography–mass spectrometry (LC-MS). In particular, one showed ARN23746 mass + 176 
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Dalton (Da) assignable to the glucuronic acid conjugation product, and the other one showed ARN23746 
mass – 14 Da assignable to the N-desmethyl derivative (Figure 26). 
Interestingly, when the rate of formation of these metabolites was compared in rat vs human liver 
homogenates, rat metabolism resulted more prone to dealkylation (Figure 26), giving rise to the N-
desmethyl derivative. Conversely, in human microsomes the main metabolic path was the conjugation 









Table 1 Preliminary absorption-distribution-metabolism-excretion properties of ARN23746  
 
Figure 26. Structure of the two main metabolites of ARN23746 identified in rat and human. 
  
Analysis Species ARN23746 
Kinetic solubility PBS pH 7.4 - > 250 µM 
Thermodynamic solubility PBS pH 7.4 - 181 µM 
t1/2 plasma mouse > 120 min  
t1/2 liver microsomes mouse > 60 min 
Residual liver compound mouse 65% 
t1/2 liver microsomes rat 189 min 
t1/2 liver microsomes human 395 min 












Altogether, these studies indicate that ARN23746 shows a satisfying preliminary ADME profile. Thus, we 
selected ARN23746 for further evaluation in vivo. 
 
7. ARN23746 does not exert significant diuretic effect in vivo 
Next, we assessed ARN23746 diuretic effect in WT and TS65Dn mice. To this aim, we treated 2-4 month 
mice with an intra peritoneal (ip) injection of ARN23746 dissolved in PBS at 0.2 mg kg
−1
, which are the 
same route of administration and dosage used for bumetanide in the previous study from our lab (Deidda, 
Parrini, et al., 2015). As a positive control, we used indeed bumetanide at the dose of 0.2 mg kg
−1
. As a 
negative control, we used the same amount of DMSO dissolved in PBS (vehicle). The day of the 
experiment, we treated WT and Ts65Dn mice with DMSO, bumetanide or ARN23746, and we placed 
them into a metabolic cage (Tecniplast) for 2 hrs, where they found free food and water. After 2 hrs, we 
collected and measured the urine volume (Figure 27A). As expected, bumetanide administration 
significantly increased the urine volume both in WT and Ts65Dn mice when compared with vehicle-
treated mice (Figure 27B). Conversely, ARN23746 treatment had no significant diuretic effect both in 
WT and Ts65Dn mice, when compared with vehicle-treated mice (Figure 27B). 
 
Figure 27. A) Schematic cartoon of the experimental protocol for the treatment of WT and Ts65Dn mice with bumetanide 
(control) and with the compound ARN23746 for the assessment of their diuretic effect. B) Quantification of the urine volume in 
mice treated with vehicle (WT, n = 13, Ts65Dn, n = 9), bumetanide (WT, n = 10, Ts65Dn, n = 10) or ARN23746 (WT, n = 12, 
Ts65Dn, n = 13). * P<0.05, two-way ANOVA Tukey’s post hoc test. 
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8. ARN23746 is able to rescue memory deficits in Down syndrome mice  
Next, we investigated ARN23746 efficacy in rescuing cognitive impairment in Ts65Dn mice, as 
previously tested with bumetanide (Deidda, Parrini, et al., 2015). In particular, we evaluated both the 
short-term working memory and the long-term hippocampus-dependent explicit memory after a 
subchronic, systemic treatment with ARN23746 (0.2 mg kg
−1
, IP, daily; Figure 28).  
 
Figure 28. Schematic cartoon of the experimental protocol for the treatment of WT (black circle in graphs) and Ts65Dn (orange 
circles in graphs) mice with the compound ARN23746 for its efficacy assessment. 
 
First, we assessed the efficacy of ARN23746 in restoring short-term memory, by testing mice in the T-
maze task (spontaneous alteration protocol, 11 trial). The test was conducted similarly to what had 
previously described for Ts65Dn mice (A. M. Kleschevnikov, P. V. Belichenko, M. Faizi, et al., 2012). In 
this test, mice are started from the base of a T-shaped maze (Figure 29, left) and they are allowed to 
choose one of the two arms (first choice). If they remember the previous choice, mice will choose the arm 
not visited in the trial before, after the first trial. The alternate choice of each arm is considered as correct, 
whereas the choice of the same arm as in the previous trial (reflective of a poor short-term memory) is 
considered as negative. The final score for each animal is calculated by the number of the correct choices 
over the total of 10 trials. Confirming data from literature (A. M. Kleschevnikov, P. V. Belichenko, M. 
Faizi, et al., 2012), Ts65Dn showed poor short-term memory in comparison to WT littermates. 
ARN23746 treatment completely rescued the number of correct choices of Ts65 mice in comparison to 





Figure 29. Left: schematic representation of the T-maze task. Right: quantification of the correct choices in mice treated with 
vehicle (WT, n = 12, Ts65Dn, n = 9) or ARN23746 (WT, n = 14, Ts65Dn, n = 12). ***P < 0.001, two-way ANOVA Tukey’s 
post hoc test.   
 
Then, we assessed the long-term memory in three independent tasks (i.e., object location, novel object 
recognition and contextual fear conditioning). We assessed spatial memory in the object location task 
(OL). The test measures the ability of mice to recognize the new location of a familiar object with respect 
spatial external cues (Figure 30, top). As previously described (Deidda, Parrini, et al., 2015), vehicle-
treated Ts65Dn mice showed impaired spatial memory, as demonstrated by a poor discrimination index 
reflective of poor discernment of the new object position. ARN23746 treatment restored the performance 
of Ts65Dn mice to the level of WT (Figure 30A). The effect of ARN23746 in the OL test was not due to 
alterations in the object preference or in the total object exploration during the acquisition phase (Figure 
30B and 30C). Interestingly, during the trial phase, Ts65Dn mice treated with ARN23746 showed a 
significant increase in exploration time (Figure 30D), possibly indicative of a more explorative interest 
forthe objects. Nevertheless, given that the exploration of the single object was normalized on the total 
exploration time for each group, the increased exploration in Ts65Dn mice treated with ARN23746 did 




Figure 30 Top, schematic representation of the object-location test. A) Quantification of the discrimination index in mice treated 
with vehicle (WT, n = 14, Ts65Dn, n = 10) or ARN23746 (WT, n = 14, Ts65Dn, n = 12). ***P < 0.001, two-way ANOVA 
Tukey’s post hoc test. B) Quantification of the percentage of time spent exploring the two objects during the acquisition phase. 
C) Quantification of the percentage of the total time spent exploring the objects during the acquisition phase. D) Quantification of 
the percentage of the total time spent exploring the objects during the trial phase. *P < 0.05,**P < 0.01, two-way ANOVA 
Tukey’s post hoc test. 
 
We next assessed the recognition memory in the novel-object recognition (NOR) test. This task measures 
the preference of mice for a novel object versus previously encountered familiar objects. As previously 
demonstrated (Deidda, Parrini, et al., 2015), Ts65Dn mice showed poor recognition memory in 
comparison to WT littermates. Interestingly, ARN23746 administration was able to completely rescue the 
poor novel-discrimination ability of Ts65Dn mice (Figure 31A). The effect of ARN23746 in NOR test 
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was not due to alterations in the object preference or in total object exploration (Figure 31B,C,D). 
Although there was a preference of ~10% of the object B within the same group in all four groups, the 
preference was not significantly different among the four groups (Figure 31B).   
 
Figure 31. Top: schematic representation of the novel-object recognition test. A) Quantification of the discrimination index in 
mice treated with vehicle (WT, n = 13, Ts65Dn, n = 11) or ARN23746 (WT, n = 15, Ts65Dn, n = 12). * P<0.05, two-way 
ANOVA Tukey’s post hoc test. B) Quantification of the percentage of time spent exploring the three objects during the 
acquisition phase. C) Quantification of the percentage of the total time spent exploring the objects during the acquisition phase. 
**P < 0.01, two-way ANOVA Tukey’s post hoc test. D) Quantification of the percentage of the total time spent exploring the 
objects during the trial phase.  
 
Finally, we evaluated associative memory in the contextual fear conditioning test (CFC). This task 
measures the freezing response that takes place after pairing of a foot shock (conditioning) with a 
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particular context represented by the grid releasing the shock (Figure 32, Top). As previously 
demonstrated (Deidda, Parrini, et al., 2015), Ts65Dn mice showed poor freezing response after the re-
exposure to the grid context 24h after conditioning. Notably, ARN23746 treatment fully restored the 
associative memory in Ts65Dn by rescuing the poor freezing response (Figure 32A), without inducing 
changes in non-associative freezing (freezing response measured in a new context; Figure 32B).  
 
Figure 32. Top, schematic representation of the contextual fear-conditioning test. A) Quantification of the freezing response in 
mice treated with vehicle (WT, n = 13, Ts65Dn, n = 11;) or ARN23746 (WT, n = 15, Ts65Dn, n = 12). * P<0.05, ** P<0.01, 
two-way ANOVA Tukey’s post hoc test. B) Quantification of the freezing response in mice treated with vehicle (WT, n = 13, 
Ts65Dn, n = 11;) or ARN23746 (WT, n = 15, Ts65Dn, n = 12) during the exposition to the new context.  
 
9. Evaluation of toxicity of ARN23746 after in vivo chronic treatment 
To assess any toxicity following ARN23746 systemic administration, we first monitored the weight of 
treated animals during the four weeks of chronic treatment. As reported in figure 33A, a four week-daily 
treatment with ARN23746 did not affect body weight, nor the general health state of the mice, as 
evaluated by daily eye assessment. Moreover, on the same animals we measured the viscera index 
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(viscera weight/body weight) for the kidneys, liver, spleen, lungs, and brain. As shown in the Figure 33B, 
chronic treatment with ARN23746 did not alter the weight of internal organs.  
 
Figure 33. A) Quantification of the body weight of WT and TS65Dn mice across the four weeks of treatment with vehicle 
(control) and ARN23746. B) Visceral index expressed as viscera weight/body weight of 5 different organs collected from WT 
and TS65Dn mice after chronic treatment with vehicle (control) and ARN23746.  
 
Moreover, we assessed the histopathological profile of liver, kidney and spleen. In particular, from each 
organ, we analyzed five sections stained with hematoxylin-eosin, marker of nucleus and cytoplasm 
respectively and gold standard of medical diagnosis. As shown in Table 2 and in figure 34, we did not 
found major abnormalities following ARN23746 chronic treatment. Indeed, across the 14 WT mice (7 
treated with vehicle and 7 treated with ARN23746) and the 9 Ts65Dn mice (4 treated with vehicle and 5 
treated with ARN23746) we found some morphological alterations in the liver of only two WT vehicle-
treated mice and one Ts65Dn vehicle-treated mouse, in one kidney of one WT vehicle-treated mouse, one 
WT ARN23746-treated mouse and one Ts65Dn vehicle-treated mouse, and in the spleen of one WT 
vehicle-treated mouse and of one Ts65Dn vehicle-treated mouse. These results are compatible with the 
individual variability already described in mice and cannot be ascribed at any toxic effect of ARN23746. 
In particular, the focal angiectasis observed in the liver could occur spontaneously and occasionally. 
Angiectasis consists of dilated sinusoidal spaces that are lined by endothelial cells. Hepatocytes adjacent 
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to angiectatis appeared normal in dimension and morphology. Moreover, these alterations were observed 
only in vehicle-treated mice. With respect to kidneys, they generally undergo rapid autolysis, which could 
determine some alteration similar to degeneration and necrosis. In our case, no significant change in 
glomerular and tubular morphology were found.  Only in one mouse was observed a cyst that may be 
congenital and should be noted as an isolated finding in the absence of other renal pathology. Finally, no 
evidence of alterations associated with chronic treatment with ARN23746 were detected in spleen except 
of two focal autolysis, however localized, observed in red pulp of two mice. 
 
 
Table 2. Number of WT and Ts65Dn mice showing a physiological or pathological morphology of liver, kidney and spleen after 
four weeks of treatment with vehicle (control) or with ARN23746.  
 







A large and fast-growing body of literature indicates that an aberrant Cl
-
 homeostasis, due to an 
imbalance in NKCC1 vs KCC2 activity and/or expression, is implicated in several neurological disorders.  
Accordingly, several studies indicated NKCC1 inhibition by bumetanide as a valuable therapeutic 
strategy to ameliorate core symptoms in a number of animal models of these neurological disorders (Ben-
Ari, 2017; Schulte et al., 2018). Moreover, several clinical trials and case studies indicate positive 
outcomes of bumetanide treatment also in patients (Ben-Ari, 2017).  
1. Current issues with a NKCC1-inhibition therapy by bumetanide. 
Although NKCC1 inhibition is a promising target for the treatment of diverse  neurodevelopmental 
disorders, a chronic treatment seems to be required. Indeed, in a clinical study demonstrating a positive 
therapeutic effect of bumetanide on ASD children, Lemonnier and colleagues found a clear trend in 
CARS test score to return to pretreatment values at the end of a 1 month wash-out period  (Lemonnier et 
al., 2012). Moreover, a week of drug withdrawal after a monthly treatment with bumetanide resulted in 
cognitive deficits in DS mice that were comparable to untreated DS mice (Deidda, Parrini, et al., 2015). 
Considering the strong diuretic effect of bumetanide (Flamenbaum & Friedman, 1982), which leads to 
hypokalemia and ionic imbalance (Lemonnier et al., 2012; Lemonnier et al., 2017), bumetanide 
repurposing is thus not a sustainable therapeutic approach that is compatible with a lifelong treatment of 
several years. In the last decades, the life expectancy of DS individuals has indeed increased dramatically, 
from just 9 years in 1930 to more than 60 years to date (Bittles et al., 2007). This is mainly attributable to 
the remarkable amelioration in medical care for the general population and in particular for people with 
DS. In particular, improvements in antibiotic treatments and vaccinations has  contributed to a decrease of 
death for pneumonia and other infections (Alsubie & Rosen, 2018). Moreover, the improved outcomes of 
cardiac surgery and the better understanding of the heart defects frequent in DS has led to increased 
survival and to better quality of life of DS subjects (Versacci et al., 2018).  
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Beside strong diuresis,  potential ototoxicity represents another severe side effect of bumetanide. In 
particular, the effects on the auditory system have proved critical for the treatment of infants. Indeed, one 
clinical trial for the repurposing of  bumetanide for the treatment of acute neonatal encephalopathy 
seizures was suspended due to induced deafness in some treated subjects (Ben-Ari et al., 2016). So far, 
diverse studies identified changes in cochlear potentials and damage in cochlear stria vascularis as the 
main ototoxic effect following loop-diuretic administration. Although the clear mechanisms underlying 
ototoxicity are still under investigation,  inhibition of sodium-potassium ATPase pump,  adenylate cyclase 
and NKCC transporters are among the most accredited mechanisms (Ding et al., 2016). In particular, 
inhibition of NKCC1 in the cochlea, (Delpire et al., 1999) and inhibition of NKCC2 expressed in 
endolymphatic sac at the membranous labyrinth (Akiyama et al., 2010; Kakigi et al., 2009) possibly 
contribute to the inner ear damage and ototoxic effect by loop diuretics which inhibit both NKCC1 and 
NKCC2. 
Finally, bumetanide could further aggravate the osmotic fluid balance (Konopacka et al., 2015)  and could 
possibly affect social behavior, sexual motivation, pair bonding and maternal responses to stress, by 
acting on vasopressinergic and oxytocinergic neurons in the hypothalamo-neurohypophyseal system. 
Indeed, NKCC2 is also expressed in these neurons, where it regulates fluid balance following dehydration 
(Konopacka et al., 2015), but possibly also all the behaviors and biological processes controlled by the 
two hormones in the CNS and in periphery.   
Thus, although clinical trials and case studies indicate positive outcomes of bumetanide treatment also in 
patients, its strong diuretic effect and consequent ionic imbalance, as well as its ototoxicity and potential 
effect on vasopressinergic and oxytocinergic neurons strongly hamper the possibility of bumetanide to 
become a reliable clinical option. In this scenario, a new compound ARN23746 able to selectively inhibit 
NKCC1 thus devoid of diuretic effects and with possibly reduced ototoxicity, osmotic imbalance  and  as 
behavioral side effects, may be a more sustainable therapeutic treatment in the future. ARN23746 as a 
potent and more selective NKCC1 inhibitor  
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Our in vitro studies demonstrated that ARN23746 is able to inhibit NKCC1 with a higher efficiency than 
bumetanide. For this assessment, we set up two different cellular assays: the chloride assay in HEK293 
cells and the calcium assay in primary neurons in culture. With the chloride assay in HEK293 cells, we 
assessed NKCC1 inhibition through indirect estimate of the Cl flux via the transporter by measuring the 
variation in intracellular Cl concentration. With the calcium assay, we assessed NKCC1 inhibition 
through evaluating the ability of our compound to revert the depolarizing GABA signaling in young 
neurons, indirectly measured as calcium influx into the cells. Interestingly, both in the case of bumetanide 
and ARN23746 the two assays produced comparable results. Conversely, furosemide, ARN22642 and 
ARN22430 showed seemingly increased potency in the calcium assay, which we demonstrated was 
attributable to the inhibition of GABAA receptor, as already known for furosemide (Korpi et al., 1995; 
Korpi & Luddens, 1997; Minier & Sigel, 2004). Notably, ARN23746 showed a NKCC1 inhibitory 
activity comparable with the activity of bumetanide at 10 µm, but displayed a higher potency than 
bumetanide at 100 µm. This sharp increase in activity in comparison to bumetanide, could suggest that 
our compound is acting by binding NKCC1 in a cooperative manner. In this type of binding, the 
occupation of the binding sites by the ligand is indeed not a linear function of the ligand’s concentration, 
and the affinity for the ligand  depends on the amount of the bound ligand (Stefan & Le Novere, 2013). 
Binding in vitro assays and dose-response curves will be necessary to further investigate the type of 
binding between ARN23746 and NKCC1. Moreover, the resolution of NKCC1structure, coupled with 
binding assays and mutagenesis studies, will elucidate how NKCC1 modulates ion permeation and how 
bumetanide and ARN23746 affect NKCC1.   
In our in vitro assays ARN23746 showed no significant inhibitory activity of NKCC2, in comparison to 
the significant inhibitory activity of bumetanide at 10 µM. Conversely, at the same concentration 
ARN23746 was able to significantly inhibit NKCC1 at levels comparable to bumetanide. Thus, the 
inhibition ratio of NKCC1/NKCC2 is markedly in favor of ARN23746 when compared to bumetanide. 
Consistently, at the in vivo dosage at which bumetanide rescued cognitive impairments but it is diuretic in 
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DS mice (0.2 mg/Kg), ARN23746 still recued cognitive deficits but it did not show any significant 
diuretic effect. Possibly, at the same dosage ARN23746 does not inhibit NKCC2 expressed in 
endolymphatic sac and/or in vasopressinergic and oxytocinergic neurons, thus reducing, at least in part, 
the ototoxic effect of bumetanide and other osmotic and behavioral side effects. These findings indicated 
ARN23746 as a promising candidate for further drug development of selective and potent NKCC1 
inhibitors. 
2. Challenges of drug development. 
Drug development is a long, arduous risky and costly process. It is characterized by numerous steps 
which range from the identification and synthesis of new chemical compounds with possible biological 
activity, to the direct screening in in vitro assays and in vivo preclinical studies in animal models to 
identify a lead compound. Then, chemical modifications of the lead compound are designed to maximize 
its therapeutic effect and minimize its side effects.  In recent years, computational drug design based on 
target-structure approaches has aided to lessen the risks, costs and duration of classical drug development 
(Chaudhari et al., 2017). Nevertheless, NKCC1 structure is still unknown. Thus, to screen for new 
NKCC1 inhibitors in libraries of pre-existing novel compounds, we applied here a ligand-based strategy, 
which took advantage of the structure of the known NKCC1-inhibitor (bumetanide, furosemide and 
asozemide). Moreover, the initial synthesis of close analogues of bumetanide guided us in the 
understanding of bumetanide’s structural motifs able to decrease the activity against NKCC2, which we 
applied to the hit compounds selected from the library screenings.  
Although these computational and other several strategies have been adopted to accelerate the process of 
drug discovery and increase the positive outcomes, pharmaceutical companies face remarkable challenges 
in improving the efficiency of the drug development process (i.e. the number of new drugs approved by 
the FDA per billion US$ spent). Actually, the cost of developing new compounds has increased from US$ 
800 million in 2001 to the currently estimated US$ 3 billion (Mak & Pichika, 2018). The decline in 
efficiency of the drug development process is possibly due to several factors, including: (a) the presence 
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of more stringent regulations to avoid risks of severe drug side-effects that occurred in the past (Notably,  
62% of new compounds in Phase IIb and Phase III clinical trials do not reach the clinic, mainly for failure 
in clinical safety and efficacy; (Mak & Pichika, 2018)); (b) the bias in target identification, which is often 
screwed toward targets that are known already;  (c) the fact that the drugs addressing the easily tractable 
targets have been already developed, and often only more difficult targets are left.  
The drug development process is even more costly and risky for compounds targeting the CNS, which is 
clearly reflected by a marked lack of new classes of compounds for the very vast majority of neurological 
disorders. This is firstly due to the many challenges in the identification of possible drug targets for 
complex CNS disorders, whose underlying pathological mechanisms are often still poorly understood. 
Moreover, lack of appropriate animal models, difficulty in brain penetration due to the presence of the 
BBB, absence of reliable biomarkers for assessment of treatment efficacy in the case of behavioral 
deficits characteristic of brain disorders, and incomplete knowledge of the natural history of CNS diseases 
have further decreased the success in developing new compounds (Gribkoff & Kaczmarek, 2017). Hence, 
many pharmaceutical companies dismissed or significantly reduced their CNS programs (Gribkoff & 
Kaczmarek, 2017). In this scenario, the identification of clear and safe targets, possibly validated in 
humans through ad hoc clinical protocols could be the first step to partially overcome the lack of new 
compounds targeting the CNS. Below, we will discuss these issues specially referring to our new 
compound ARN23746.  
3. NKCC1 as a molecular target for the rescue of diagnostic behaviors in brain disorders 
The finding that systemic treatment (i.e., i.p. or per os) by the NKCC1 inhibitor bumetanide can rescue 
diagnostic impaired behaviors in animal models and patients has suggested NKCC1 as a possible 
molecular target in a number of brain disorders. Nevertheless, this notion has been challenged by the fact 
that bumetanide’s suboptimal BBB penetration has been considered in recent years incompatible with 
NKCC1 inhibition in vivo (Puskarjov, Kahle, et al., 2014; Romermann et al., 2017; Tollner, Brandt, 
Romermann, et al., 2015; S. Wang et al., 2015) For example, after 1 hour from i.p. injection of 0.3 mg/kg 
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in neonatal rats, only ∼1 ng/g of bumetanide per brain tissue was detected. This corresponds 
approximately to a concentration of ∼3 nM, which is orders of magnitude lower than the ∼200–300 nM 
half-maximal inhibitory concentration of bumetanide required for NKCC1 inhibition in vitro (Puskarjov, 
Kahle, et al., 2014). Although this incompatibility between the in vivo concentration reached by 
bumetanide after systemic injection and the half-maximal inhibitory concentration in vitro is of great 
concern, one should be careful to directly translate in vitro results to the in vivo situation, as the 
bumetanide in vivo concentration required for biological effects on intracellular Cl
-
 concentration is still 
not known. Moreover, it is not known to what extent intracellular concertation should be restored to lead 
to positive behavioral outcomes, and finally this extent could vary from behavior to behavior and across 
the diverse brain disorders.  
Besides regulation of intraneuronal Cl
-
 concentration by inhibition of brain NKCC1, bumetanide could act 
by being a diuretic, thus through its well-known osmotic regulation and/or by altering ionic balance 
(Hochman, 2012). Moreover, being a small molecule, bumetanide could have unpredictable other targets 
both in the brain and out of the brain that may in fact be relevant to the rescue of the diverse behaviors in 
the specific brain disorders (Brandt et al., 2018). Interestingly, few studies tested the effectiveness of 
bumetanide following direct brain infusion. For example, bumetanide infusion in the brain lateral 
ventricle rescued the spatial memory deficit in the R6/2 mouse model of Huntington’s disease (HD) 
comparably to systemic administration (Dargaei et al., 2018). Moreover, intra-amygdala infusion of 
bumetanide inhibited the acquisition of the fear-potentiated startle response, as previously observed 
following systemic administration (Ko et al., 2018). Although these studies suggest the brain as the 
possible site of action for pro-cognitive and anxiolytic activity of bumetanide in HD and anxiety disorders 
respectively, the causal link between NKCC1 inhibition and rescue of behavioral deficits in diverse brain 
disorders remains elusive. The recent evidence from members of the Cancedda laboratory (and reported 
here) showing that NKCC1 downregulation by RNA interference through a single viral injection in the 
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hippocampus was able to rescue learning and memory deficits in adult Ts65Dn mice clearly identified 
NKCC1 as molecular target for cognitive impairment in DS. 
Here, we demonstrated that also our newly synthesized NKCC1 inhibitor, is able to rescue cognitive 
deficits in adult Ts65Dn mice, further strengthening the notion that brain NKCC1 inhibition is causally 
linked to rescue of behavioral deficits in DS mice. Interestingly, given that most of the brain defects 
occurring in DS as well as in the other ND described above originate during development, an early 
therapeutic strategy in pups could be even more beneficial than in the treatment in adults. Indeed, acting 
when neuronal networks are still plastic during development could ameliorate symptoms that treatments 
in adulthood were not able to reverse, possibly due to present miswiring in the neuronal circuit. For 
example, bumetanide treatment in adult Ts65Dn mice failed to rescue hyperactivity and seizure 
susceptibility, whereas an earlier treatment could be beneficial (Deidda, Parrini, et al., 2015). Moreover, 
early pharmacological treatments in NDs could also lead to beneficial behavioral effects that persist into 
adulthood. This could eliminate or most likely reduce the need for chronic pharmacological treatments in 
adulthood.  
Notably, the new selective NKCC1 inhibitor is devoid of the diuretic effect, thus indicating that the 
osmotic regulation and/or the alteration of ionic balance are, at least, not the only mechanism by which 
bumetanide restores cognition in DS.  
One intriguing hypothesis is that bumetanide and ARN23746, besides binding to NKCC1 expressed in the 
brain, could also act by binding to NKCC1 expressed at the BBB and/or at the choroid plexus. 
Interestingly, high NKCC1 expression in the choroid plexus has proved fundamental for the formation of 
the CSF. Accordingly, NKCC1 inhibition by bumetanide or furosemide reduces CSF production 
(Steffensen et al., 2018). Thus, bumetanide and ARN23746 by acting at the NKCC1 expressed at the 
BBB and at the choroid plexus could decrease the potassium (K
+
) concentration in the CSF, leading to a 
decrease of extracellular K
+
 concentration in the brain. We hypothesize that this could hamper the 
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cotransport of Cl by reducing the activity of  NKCC1 expressed at the plasma membrane of the neurons, 
resulting in a net decrease of intracellular Cl concentration.  
In the last few weeks, we have started investigating this hypothesis by assessing NKCC1 function at 
decreasing extracellular K
+
 concentrations, taking advantage of the chloride assay previously described. 
Interestingly, we found that lowering the K
+
 concentration in the extracellular solution determined a 
decrease in Cl
-  
influx in HEK393 cells (estimated as a lower decrease in mbYFPQS fluorescence), thus 
preliminarily confirming our hypothesis (Figure 35). Notably, the actions of NKCC1 inhibitors in the 
brain parenchyma or at the BBB/choroid plexus could occur simultaneously, thus leading to a synergic 
effect on lowering the intracellular Cl concentration in neurons.   
 
Figure 35. Quantification of the Cl- influx via NKCC1, following variation in extracellular K+ with the chloride assay. Less 
decrease in fluorescence (upon NaCl application) was observed lowering the extracellular K+, indicating that less chloride is 
entering in to the cells via NKCC1.  
 
4. Clinical trials with bumetanide to validate NKCC1 as a molecular target in humans. 
Currently, a total of 15 clinical studies (case , pilot, phase I and phase II studies) have been performed to 
assess the therapeutic effect of bumetanide in ASD (Du et al., 2015; Hadjikhani et al., 2018; Hadjikhani et 
81 
 
al., 2015; Lemonnier & Ben-Ari, 2010; Lemonnier et al., 2012; Lemonnier et al., 2013; Lemonnier et al., 
2017), Fragile X (Lemonnier et al., 2013), Asperger syndrome (Grandgeorge et al., 2014), 15q11.2 
duplication syndrome (Bruining et al., 2015), neonatal seizures and temporal lobe epilepsy (Eftekhari et 
al., 2013; Kahle, Barnett, et al., 2009; Pressler et al., 2015), schizophrenia (Lemonnier et al., 2016; 
Rahmanzadeh, Eftekhari, et al., 2017) and Parkinson disease (Damier et al., 2016).  Interestingly, in all 
these studies (beside the Nemo trial failed because of the bumetanide’s ototoxic effect (Ben-Ari et al., 
2016)) bumetanide administration resulted in amelioration of the core diagnostic symptoms of these 
pathologies.   
Besides being a first (although not ideal) therapeutic option for many unmet medical needs, these results 
are of great importance in the attempt to pursue a full-fledged drug discovery program for potent and 
selective novel NKCC1 inhibitors because:  
1) They validate NKCC1 as a valuable molecular target also in patients. Interestingly, upregulation 
of NKCC1 was reported in samples from DS (Deidda, Parrini, et al., 2015) and schizophrenic 
subjects (Dean et al., 2007; Hyde et al., 2011). The investigation of NKCC1/KCC2 expression 
also in all the other neurological disorders that benefit from a treatment with bumetanide could 
further widen the knowledge of the molecular mechanism underling these diseases. Interestingly, 
studies performed in animal models indicate that most of these conditions are characterized by 
KCC2 (rather than NKCC1) dysregulation  (Di Cristo et al., 2018; Eftekhari, Shahrokhi, et al., 
2014; Tyzio et al., 2014; Wu, Che, et al., 2016; Wu, Shao, et al., 2016). This indicates that, no 
matter which one of the two transporters is dysregulated, it is the NKCC1/KCC2 ratio imbalance 
that needs to be targeted to restore the physiological Cl
-
 homeostasis. In this respect, the possible 
combinational therapy with the newly discovered KCC2 activator CLP257 (Gagnon et al., 2013; 
Gagnon et al., 2017), could increase the beneficial effect of bumetanide (and possibly 




2) They provide specific indications regarding the planning of the clinical trial protocols for each of 
the disorder where bumetanide has been tested. The same protocols could be easily applied also 
to ARN23746, when ready to be tested in clinic. 
 
5. Concluding remarks. 
Altogether, our studies identified a new potent and selective NKCC1 inhibitor, ARN23746. The usage of 
this compound to rescue cognitive impairment in DS mice independent of the diuretic effect (or other 
NKCC2-dependent effects) typical of bumetanide has shed light into the mechanism of NKCC1-
dependent regulation of learning and memory. Moreover, being devoid of diuretic effect in vivo, 
displaying excellent solubility and metabolic stability in vitro and showing no toxicity following in vivo 
chronic treatment, ARN23746 could represent in the future a solid and sustainable therapeutic strategy for 















HEK cell culture and transfection 
HEK 293 cells were cultured in Dulbecco’s MEM (DMEM) (Life Technologies) supplemented with 10% 
fetal bovine serum (Life Technologies), 1% L-glutamine, 100 U/ml penicillin, and 100 μg/ml 
streptomycin (Life Technologies) and maintained at 37°C in a 5% CO2 humidified atmosphere. The cells 
were transfected with Lipofectamin 2000 (Life Technologies). In particular 3 million HEK cells were 
plated in a 10 cm cell culture dish and were loaded with a transfection solution constituted by 5 ml of 
DMEM (Dulbecco’s Modified Eagle Medium, (Life Technologies)), 4 ml Opti-MEM (Life 
Technologies), 8 ug of DNA plasmid coding for NKCC1, or NKCC2 together with the Cl-sensitive YFP 
and 32 ul of Lipofectamin for each condition. After 4 hour the cells were collected and plated in a 96-well 




Neurons culture  
Primary cultures of dissociated hippocampal neurons were prepared from E18 C57Bl6/J plated in the 96-
well plate at density of 30,000 cells per well. Neurons were maintained in Neurobasal medium 
(Invitrogen) supplemented with  2% B-27 supplement (Invitrogen) , 0.5 mM glutamine (Invitrogen ), 50 
U/mL of penicillin (Invitrogen) and 50 μg/mL of streptomycin (Invitrogen). The cells were incubated at 
37°C and 5% CO2 until DIV 3 and then used for the calcium kinetic assay.  
 
Drug Preparation for in vitro and in vivo assays   
All the tested compound in vitro were dissolved in DMSO in a stock solution of 10mM. Then, depending 
on the final concentration used in the assays (10µM or 100 µM), the compound stock solution was 
dissolved 1:1000 or 1:100 in assay buffer. As control we used assay buffer supplemented with 0.1% 
DMSO or 1% DMSO respectively. For the in vivo experiments, bumetanide and ARN23746 were 
dissolved in DMSO in a stock solution of 1 mg/ml. The day of the injection the stock solution was 
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dissolved in PBS at the concentration of 0.02 mg/kg and injected in a volume of 10ul/g to have a final 
concentration of 0.2 mg/kg.    
 
Western Blot 
Cell culture samples were homogenized in RIPA buffer (1% NP40, 0.5% Deoxycholic acid, 0.1% SDS, 
150 mM NaCl 1 mM EDTA, 50 mM Tris, pH 7.4) containing 1% (v/v) protease and phosphatase 
inhibitor cocktails (Sigma). Then, after 30’ incubation in ice, the samples were clarified through 
centrifugation at 20,000 x g. The protein concentration of samples was determined with BCA kit (Pierce). 
Equivalent amounts of protein (20 µg)  were loaded on the 4-12% Bis-Tris NuPAGE precast gels 
(Invitrogen) and the electrophoresis were performed in NuPage apparatus. Next, gels were transferred 
onto nitrocellulose membranes (Whatman).  The equal amount of protein loaded was verified by staining 
with 0.1% Ponceau. Thus, membranes were blocked for 1 h in 5% milk in Tris-buffered saline (10 mM 
Tris, 150 mM NaCl, pH 8.0) plus 0.1% Tween- 20 and incubated overnight at 4 °C with primary 
antibodies for: rabbit anti-actin (1:10000, Sigma), mouse anti-NKCC1 (clone T4; 1:4000, Developmental 
Studies Hybridoma Bank), rabbit anti-KCC2 (1:4000, Millipore) and sheep anti-NKCC2 (1:2000, MRC-
PPU). Next, membranes were washed and incubated for 2 hr at room temperature with  HRP-conjugated 
goat secondary antibodies (Thermo; 1:5000). Thus, membranes were developed with SuperSignal West 
Pico chemiluminescent substrate and the chemiluminescent signals were acquired on the LAS 4000 Mini 
imaging system (GE Healthcare). Bands were later quantified by measuring the mean intensity of the 
band signal using ImageJ. 
 
Chloride kinetic assay in HEK cells  
We performed the chloride kinetic assay on the cells plated in the 96-well after 48 hrs from the 
transfection. This assay was based on the use of a Cl sensor (Cl-sensitive membrane-targeted YFP, 
mbYFPQS, Addgene)(Watts et al., 2012) to measure the NKCC-driven changes in intracellular Cl. 
85 
 
Briefly, we transfected HEK293 cells with NKCC1 or NKCC2 or mock construct (control) together with 
the Cl-sensitive YFP. After 2DIV, we treated the cells with bumetanide and furosemide (as positive 




 Gluconate, 15mM HEPES pH 7.4, 50 mM Glucose, 1mM Na2HPO4, 1 mM 
NaH2PO4, 1 mM MgSO4, 1 mM CaSo4 * 2H2O  ). The different tested compounds and drugs were loaded 
at a concentration of 10 and 100 µM.  After 30 min of incubation, we loaded the plate onto the Victor 3V 
(Perkin Elmer) where we monitored the fluorescence decrease upon the application of  74 mM NaCl. In 
detail, the chloride sensitive YFP was excited at 490 nm and detected at 520 nm and the time course 
fluorescent data were recorded over a period of 80 s. For each well we performed a continuously 
recording  fluorescence for 20 s of  baseline and for 60s after 74 mM NaCl injection (20 µl of a 6X NaCl).  
    
Calcium kinetic assay 
Calcium kinetic assay was performed on hippocampal neurons prepared from mouse C57Bl/6J embryos 
on E18, and plated in a 96 well plate. At 3 DIV the neurons were loaded with a calcium-sensitive day 
(Fluo4, Invitrogen) in extracellular solution (145 mM NaCl, 5 mM KCl, 10 mM HEPES, 5.55 mM 
Glucose, 1 mM MgCl2, 2 mM CaCl2). After 15 min neurons were treated with bumetanide (as a positive 
control) or each of our best compounds (10, 100 µM) in extracellular solution for 15 min. Thus we loaded 
the plate onto the Victor 3V (Perkin Elmer)  and we monitored the level of fluorescence upon application 
of GABA (100 µM, for 20 sec). To test for neuronal viability, we also applied KCl (90 mM, for 40 sec) 
after GABA treatment. To quantify the effect of bumetanide and our new compounds on NKCC1 
inhibition, we thus normalized the fluorescence values upon GABA application to the fluorescence levels 






Neurons from hippocampal cell cultures (DIV12-20) were recorded at room temperature (22-24°C) in an 
extracellular solution containing in mM: 145 NaCl, 5 KCl, 10 HEPES, 5.55 Glucose, 1 MgCl2, 2 CaCl2. 
Cells were visualized with an upright microscope (Olympus BX51WI) with infrared differential 
interference contrast optics. Patch pipettes (3-5 MΩ) were filled with an intracellular solution containing 
in mM: 100 K-Gluconate, 45 KCl, 10 HEPES, 3 MgCl2, 2 MgATP, 0.6 EGTA and 0.3 NaGTP; GABA 
currents were evoked by keeping the cell’s membrane potential at -65 mV and puffing 20 µM GABA (10 
psi, 20-50 ms) using a Picospritzer III (Parker Instrumentation). Access resistance (Ra) was monitored 
during voltage-clamp recordings and traces with more than 25 MΩ Ra or a variation bigger than 20% 
between different sweeps were discarded. Evoked GABA-currents were obtained by averaging 5 sweeps 
for each experimental condition. Signals were sampled at 20 kHz and low pass filtered at 10 kHz with an 
Axon Multiclamp 700B (Molecular Devices). 
MQAE intracellular chloride imaging 
Imaging of intracellular Cl
-
 in hippocampal neurons was performed with the fluorescent chloride-sensitive 
indicator MQAE [N-(Ethoxycarbonylmethyl)-6-Methoxyquinolinium-Bromide] as previously described 
(Deidda, Parrini, et al., 2015). MQAE dye detects Cl
-
 ions via diffusion-limited collisional quenching, 
resulting in a concentration-dependent decrease of fluorescence emission upon an increase in Cl
-
 
concentration (Verkman et al., 1989). Hippocampal neurons at 15 DIV were loaded with 5 mM MQAE 
(Molecular Probes) and with the different treatment, DMSO (0.1 %, negative control),  furosemide (10 
µM, positive control), bumetanide (10 µM, positive control), ARN23746 (10 µM)  for 30 minutes at 
37°C. Coverslips were then transferred to a holding chamber and perfused (2 mL/min) with extracellular 
solution (NaCl 124 mM, KCl 5 mM, CaCl2 2 mM, MgCl2 1 mM, Hepes 10 mM, D-glucose 5.5 mM, pH 
7.4) with addition of the drug/compound tested  at 25°C for 5 minutes before imaging. Images were taken 
with a Nikon A1 scanning confocal microscope equipped with a 20X air-objective (NA 0.75). MQAE 
was excited with a 405 nm diode laser and fluorescence collected with a 525/50 nm band-pass emission 
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filter. All excitation and acquisition parameters (laser intensity, PMT offset and gain) were keep constant 
throughout experiments. Image analysis was performed with NIS-Elements software (Nikon) by 
measuring the mean fluorescent intensity of regions of interest (ROIs) centered on the cell body of 
individual neurons expressing from 6 randomly-selected fields for each coverslip. For each experiment, 
the average fluorescent intensity of all ROIs from a coverslip was normalized to the average fluorescent 
intensity of control samples (WT neurons treated with DMSO) in the same experiment. Pseudo-color 
images were generated by ImageJ software (http://rsbweb.nih.gov/ij/). 
 
Animals and treatment  
Ts65Dn and WT mice were generated by repeated backcross of Ts65Dn female  to C57BL/6JEi x 
C3SnHeSnJ (B6EiC3) F1 males (obtained from the Jackson Laboratories). Animals were genotyped by 
PCR as previously described by Duchon, A., et al.2011. Animals aged between 8 and 16 weeks were used 
for experiments. Both males and females were used for the analysis of diuresis; only males were used for 
behavioral experiments. Ts65Dn and WT littermates were randomly assigned to vehicle groups (2% 
DMSO in saline), bumetanide  (Sigma, 0.2 mg/Kg body weight)  or ARN23746 (0.2 mg/Kg body weight)  
or, and treated daily by intraperitoneal injection (i.p.). On the day of behavioral testing, injection was 
performed at least 1 hour before the beginning of the task.  
 
Behavioral testing  
Mice were tested after 1 week of treatment with four different tasks. During the behavioral experiment, 
animals were continuously daily treated. The tasks were video recorded and then analyzed manually in 
blind. Briefly:  
 
Object Location test (OL). The test evaluates the spatial memory by measuring the ability of mice to 
recognize the new location of a familiar object. The test was performed in a grey acrylic arena (44x44 
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cm). Mice were first habituated to the chamber for 15 min on the day 1. The next day, during the 
acquisition phase mice were exposed to 2 identical objects for 15 min. After 24 hours, during the test 
session, one of the two objects was moved to a novel location and the mice were tested for their ability to 
recognize the new location of the object for 15 min. After each trial the objects and the arena were 
cleaned with 70% ethanol. The time spent exploring each object was calculated by measuring the second 
when mice show investigative behavior (i.e., head orientation, sniffing occurring within < 1.0 cm) or clear 
contact the object with the nose. A discrimination index was calculated as the percent time spent 
investigating the object in the new location minus the percent time spent investigating the object in the 
old location [Discrimination Index = (New Object Location Exploration Time/Total Exploration Time X 
100) – (Old Object Location Exploration Time/Total Exploration Time X 100].  
 
Novel Object recognition test (NOR). The test evaluates the long-term object recognition memory by 
measuring the ability of mice to recognize a new object respect to the familiar ones. The test was 
performed in a grey acrylic arena (44*44 cm). In the first day, mice were habituated to the arena by freely 
exploring the chamber for 15 minutes. The second day during the acquisition phase mice were free to 
explore 3 different objects for 15 min. After 24 hours, one of the object used during the acquisition phase, 
was replaced with a novel object and the mice were tested for their ability to recognize the new object for 
15 min. The object used during the test were different in shape, color, size and material. After each trial 
the objects and the arena were cleaned with 70% ethanol. The time spent exploring each object was 
calculated by measuring the second when mice show investigative behavior (i.e., head orientation, 
sniffing occurring within < 1.0 cm) or clear contact the object with the nose. The time spent exploring 
each object, expressed as a percentage of the total exploration time, was measured for each trial. The 
discrimination index was calculated as the difference between the percentages of time spent investigating 
the novel object and the time spent investigating the familiar objects: discrimination index = (novel object 
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exploration time/total exploration time*100) - (familiar object exploration time/total exploration time 
*100).  
 
Contextual fear conditioning test (CFC). The test evaluates the long-term associative memory by 
measuring the freezing time of the animals placed in a place where 24hrs before received an adverse 
stimulus (electric shock).The experiments were performed  in a fear conditioning system (TSE) consisting 
of a transparent acrylic conditioning chamber (23x23 cm) equipped with a stainless-steel grid floor. Mice 
were held outside the experimental room in their home cages prior to testing and individually transported 
to the conditioning apparatus in standard cages. The chamber was cleaned with 70% ethanol after each 
trial. Mice were placed in the conditioning chamber and they received one electric shock (2s, 0.75mA 
constant electric current) through the floor grid 3 minutes later. Mice were removed 15s upon the shock. 
24 hours later, mice were placed in the same chamber for 3 minutes and they were moved to a new 
context (black chamber with plastic gray floor and vanilla odor) after 2 hours. The freezing behavior was 
scored by a trained operator blinded to the experimental groups. 
T-Maze. The T-maze test (spontaneous alteration protocol, 11 trials)evaluate the short term memory by 
analyzing the correct choice of the unexplored arm. The test was conducted similarly to what previously 
described for Ts65Dn mice (A.M. Kleschevnikov et al., 2012). The T-maze apparatus was made of black, 
opaque, acrylic plastic and consisted of a start arm and two perpendicular goal arms each equipped with a 
sliding door. For each trial, a mouse was first confined in the start chamber and after 20 seconds the 
sliding door was removed. After the mouse had entered (with all four limbs) in one of the two goal arms, 
the opposite goal arm was closed with the corresponding sliding door. The mouse was left to explore the 
remaining part of the apparatus and, when the animal spontaneously returned to the start chamber, the 
previously closed goal arm was opened. The mouse was then given the possibility to choose again one of 
the two goal arms. The procedure was repeated 11 times (for a total of 10 possible alternations). Entry 
90 
 
into a goal arm opposite to the one previously chosen was defined as a correct alternation, whereas entry 
into the previously visited arm was defined as non-correct alternation. Alternation score was defined as 
the percentage of correct alternations (i.e., left–right or right–left) over the total number of possible 
alternations. 
 
For behavioral experiments, we adopted the following exclusion criteria independently of genotype or 
treatment (before blind code break). In the CFC test, we excluded mice showing very high non-
associative freezing in the new context: more than 30 seconds freezing during the 3 minutes test. In the 
OL and NOR test, we excluded animals showing very low explorative behavior: less than 10 seconds of 
direct objects exploration during the 15 minutes test. In the T-maze test we excluded mice not concluding 
the 10 trials within 10 minutes of test. 
 
Diuresis Analysis  
Diuresis analysis were performed tacking advantage of metabolic cages (Tecniplast) which are equipped 
with a funnel and a plastic cone able to separate urine and feces. After ip treatment with vehicle, 
bumetanide or ARN23746 animals were placed inside the metabolic cages (one animal for each cage) 
where free food and water are available. After two hours mice are returned in their home cages and urine, 
collected in a vial, are measured and stored at -80°C.  
 
Statistical analysis  
The results are presented as the means ± SEM. The statistical analysis was performed using SigmaPlot 
(Systat) software. Where appropriate, the statistical significance was assessed using the following 
parametric test: Student’s t test one-way ANOVA followed by Dunnet post hoc test, two-way ANOVA 
followed by all pairwise Tukey or Holm-Sidak post hoc test. In case of normal distribution or equal 
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variance assumptions were not valid, statistical significance was evaluated using Mann-Whitney Rank 
Sum Test, Kruskal-Wallis One Way ANOVA with Dunn’s post hoc test or ANOVA on ranks followed by 
all pairwise Dunn’s post hoc test. P values < 0.05 were considered significant. 
 
Ethical approval declaration  
A veterinarian was employed to maintain health and comfort of the animals. Mice were housed in filtered 
cages in a temperature-controlled room with a 12:12 hour dark/light cycle with ad libitum access to water 
and food. All animal experiments were performed in accordance with the guidelines established by the 
European Community Council Directive 2010/63/EU of September 22nd, 2010 and were approved by the 
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